Original Article
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
N Engl J Med 2010; 363:2587-2599December 30, 2010DOI: 10.1056/NEJMoa1011205
Comments
open through January 4, 2011
- Abstract
Background
Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.
Methods
We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC–TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections.
Results
The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC–TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC–TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC–TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57).
Conclusions
Oral FTC–TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Kaplan–Meier Estimates of Time to HIV Infection (Modified Intention-to-Treat Population).Article Activity
- Article
A total of 2.7 million new infections with the human immunodeficiency virus (HIV) were diagnosed worldwide in 2008, according to the Joint United Nations Program on HIV/AIDS (UNAIDS). Combination antiretroviral therapy for patients with HIV infection restores health and may decrease the transmission of the virus to uninfected partners.1 Therapy also decreases mother-to-child transmission.2
Postexposure chemoprophylaxis is recommended after occupational or nonoccupational exposure to HIV-infected fluids.3 The use of such chemoprophylaxis requires that people recognize when they might have been exposed to HIV and that they start therapy within 72 hours. Both challenges are substantial limitations to the use of postexposure chemoprophylaxis.4,5
We selected emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) combination therapy in a single tablet (FTC–TDF) for evaluation of preexposure prophylaxis because of several favorable characteristics.6 (Details are provided in the introduction in the Supplementary Appendix, available with the full text of this article at NEJM.org.) The protective activity of FTC and TDF has been shown in mice transplanted with human immune cells7 and in nonhuman primates.8-10 In these studies, there were increased levels of efficacy when both agents were used together, as compared with the use of either agent alone. The administration of the drug both before and after exposure was important for maximizing the protective benefit. 11
Daily preexposure prophylaxis with oral TDF had an acceptable side-effect profile in a trial involving West African women.12 A tenofovir 1% vaginal gel reduced HIV infection rates by 39% among women.13 Men and transgender women who have sex with men are disproportionately affected by the global epidemic.14,15 Surveys of such persons in the United States indicate that the current use of preexposure prophylaxis is rare, although the majority would consider such use if evidence of safety and efficacy became available.16,17
In this multinational study, called the Preexposure Prophylaxis Initiative (iPrEx) trial, we aimed to evaluate the safety and efficacy of once-daily oral FTC–TDF as compared with placebo for the prevention of HIV acquisition among men and transgender women who have sex with men.
Methods
Protocol Development
We developed the concept and protocol for this study using methods that came to be approved as “good participatory practices” by UNAIDS.18 The development of the protocol was sponsored by the National Institute of Health's Division of Acquired Immunodeficiency Syndrome (DAIDS). The protocol was approved by national government public health authorities in Peru, Ecuador, South Africa, Brazil, Thailand, and the United States and by the ethics committee at each site. All subjects provided written informed consent. The study coordinator vouches for the fidelity of the report to the protocol. The study protocol is available at NEJM.org, and a detailed description of the methods is provided in the Supplementary Appendix.
Study Population and Randomization
Inclusion criteria were male sex at birth, an age of 18 years or older, HIV-seronegative status, and evidence of high risk for acquisition of HIV infection. Subject codes were randomly assigned in blocks of 10, stratified according to site. The subject codes were assigned consecutively at the study sites to eligible subjects at the time of the first dispensation of a study drug. Serologic testing for hepatitis B was performed at screening.
Study Visits
Study visits were scheduled every 4 weeks after enrollment. Each 4-week visit included drug dispensation, pill count, adherence counseling, rapid testing for HIV antibodies, and taking of a medical history. Chemical and hematologic analyses were performed at weeks 4, 8, 12, 16, and 24 and every 12 weeks thereafter. During screening, a computer-assisted structured interview collected information about education level, self-identified sex, and alcohol use, along with subjects' perceived study-group assignment at week 12. High-risk behavior was assessed by interview every 12 weeks, and physical examinations and evaluations for sexually transmitted infections were performed at least every 24 weeks. Visits through May 1, 2010, are included in this report of the primary analysis of safety and efficacy. The visit cutoff date was set by the study sponsor without any access to interim findings and was intended to ensure observation of the targeted number of seroconversion events (85). The use of study drugs was intensively monitored and promoted (for details, see Methods in the Supplementary Appendix).
Standard Prevention Interventions
At every scheduled visit, subjects received a comprehensive package of prevention services, including HIV testing, risk-reduction counseling, condoms, and diagnosis and treatment of symptomatic sexually transmitted infections, including gonorrhea and chlamydia urethritis, syphilis, and herpes simplex virus type 2 (HSV-2). In addition, at 24-week intervals, subjects were screened for asymptomatic urethritis, syphilis, antibodies to HSV-2, and genital warts and ulcers; treatment was provided when indicated. Sexual partners were offered treatment of sexually transmitted infections that were diagnosed in the subject. Subjects were linked to local prevention and treatment services when required to receive standard-of-care services. All subjects were instructed to protect themselves from HIV with conventional methods, since they were unaware of their study-group assignment. Subjects who reported a recent unprotected exposure to an HIV-infected partner were referred for postexposure prophylaxis (at sites where such therapy was available), and the administration of a study drug was temporarily suspended. Vaccination against hepatitis B virus (HBV) was offered to all susceptible subjects.
Laboratory Testing
Testing for HIV antibody was performed on whole blood with the use of two different rapid tests at every scheduled visit, and reactive rapid tests were tested with the use of Western blot analysis of serum (Figure S1 in the Supplementary Appendix). Subjects with failed rapid tests were retested during the visit. HIV plasma RNA testing with the use of an assay with a lower limit of quantitation of 40 copies per milliliter was performed if seroconversion was detected within 12 weeks after enrollment. RNA testing was also used to identify the first date of laboratory evidence of infection for the as-treated analysis. Testing for drug-resistance genotyping and phenotyping was performed with the use of clinically validated assays on the basis of the viral load at the seroconversion visit.
Subgroup Analysis of Drug Levels
A prespecified subgroup analysis was performed to investigate whether drug levels correlated with protective effect. Subjects with HIV infection were matched with two control subjects, one from each study group who were selected from among seronegative subjects, according to study site (Figure S5 in the Supplementary Appendix). Plasma was tested for the presence of FTC and tenofovir (TFV), and peripheral-blood mononuclear cells were tested for FTC triphosphate (FTC-TP) and TFV diphosphate (TFV-DP), which are the active intracellular metabolites of FTC and TFV, respectively, with the use of validated liquid chromatography and tandem mass spectrometry assays.
Study Oversight
The study was designed by four of the investigators in collaboration with all the site investigators and communities. DAIDS reviewers approved the protocol, which was developed by the study investigators, and monitored the conduct of the trial at study sites. The Bill and Melinda Gates Foundation also provided funding but did not have a role in protocol development or site monitoring. Gilead Sciences donated both FTC–TDF and placebo tablets and provided travel-related support for meetings conducted by non-Gilead investigators. The role of Gilead Sciences in the development of the protocol was limited to sections regarding the handling of the study drugs. Neither Gilead Sciences nor any of its employees had a role in the accrual or analysis of the data or in the preparation of the manuscript. DAIDS agreed to give Gilead 30 days to comment on the manuscript, but there was no agreement to accept suggestions. The first author wrote the first draft of the manuscript (except for the drug-level sections, which were drafted by another investigator) and decided to submit the manuscript for publication. The protocol statistician and data manager vouch for the accuracy of the data, and the protocol chair and site investigators vouch for the completeness of the reported data.
Statistical Analysis
Data were collected on case-report forms and faxed to a DataFax server at DF/Net Research. It was determined that the observation of 85 incident HIV infections would yield a power of at least 80% with a one-sided alpha level of 0.05 to reject a null hypothesis of efficacy of 30% or less if the true efficacy were 60% or more. The modified intention-to-treat analysis included available data for all subjects except those with HIV RNA detected in their enrollment sample. The as-treated analysis used a time-dependent covariate indication as to whether the subject was known to fall below the prespecified level of study-drug compliance (50%) on any of the following: records of study-drug dispensation alone, pill-use calculation on the basis of study-drug dispensation and returns, and subjects' self-report. For the as-treated analysis, pills from unreturned bottles were assumed to have been taken, and late visits were included in the analysis if the last dispensation allowed pill use on 50% or more of days. Safety analyses included all subjects.
Results
Study Subjects
Of 4905 subjects who were screened, 2499 were enrolled in the study from July 10, 2007, through December 17, 2009, at 11 sites in six countries (Figure 1Figure 1
Enrollment and Outcomes.). The baseline characteristics of the two study groups were similar (Table 1Table 1
Baseline Characteristics of the Subjects.). All subjects were born male, although 29 (1%) reported their current gender identity as female. The ages of the subjects ranged from 18 to 67 years; the FTC–TDF group was on average 9 months older than the placebo group (mean age, 27.5 vs. 26.8 years; P=0.04).Among HBV-susceptible subjects at screening, 94% accepted HBV vaccination. We enrolled 13 subjects with chronic HBV infection that was detected at screening, and acute HBV infection was reported as an adverse event in 3 additional subjects (2 in the FTC–TDF group and 1 in the placebo group) after enrollment when elevated liver aminotransferase levels were observed. All the HBV infections resolved with detectable levels of immunity.
Follow-up and Adherence
The cohort was followed for 3324 person-years with a variable duration of observation (median, 1.2 years; maximum, 2.8 years) (Figure 1). There were no significant trends in visit completion rates over time. Most subjects said they did not know their study-group assignment at week 12, and those who guessed their assignment were evenly distributed between the two groups (Table S3 in the Supplementary Appendix). No subjects were told their study-group assignment during the course of the trial. A study drug was temporarily discontinued in 21 subjects (8 in the FTC–TDF group and 13 in the placebo group) so that they could receive postexposure prophylaxis for HIV (P=0.28).
The rate of self-reported pill use was lower in the FTC–TDF group than in the placebo group at week 4 (mean, 89% vs. 92%; P<0.001) and at week 8 (mean, 93% vs. 94%; P=0.006) but was similar thereafter (mean, 95% in the two groups). At each visit, a portion of subjects (approximately 6%) did not report the number of pills missed. The percentage of pill bottles returned was 66% by 30 days and 86% by 60 days. The rate of pill use that was estimated according to pill count also increased during the first 8 weeks and then remained stable at a median ranging from 89 to 95%, depending on whether pills from unreturned bottles were counted as having been taken or not taken. On the basis of pill-dispensation dates and quantities, the rate of pill use decreased during the first year, from 99% to 91%, a trend that contrasted with pill counts and self-report, which indicated an increased rate of use.
Sexual Practices
Sexual practices were similar in the two groups at all time points (P=0.97) (Figure S2 in the Supplementary Appendix). The total numbers of sexual partners with whom the respondent had receptive anal intercourse decreased, and the percentage of those partners who used a condom increased after subjects enrolled in the study. There were no significant between-group differences in the numbers of subjects with syphilis (P=0.49), gonorrhea (P=0.74), chlamydia (P=0.43), genital warts (P=0.53), or genital ulcers (P=0.62) during follow-up (Table S4 in the Supplementary Appendix).
Safety
In testing for elevations in serum creatinine levels, there were 41 instances of elevations that were at least 1.1 times the upper limit of the normal range or more than 1.5 times the baseline level. Of these elevations, 26 (2%) were in the FTC–TDF group and 15 (1%) were in the placebo group (P=0.08). Two of these elevations increased in grade, accounting for a total of 43 creatinine adverse events (Table 2Table 2
Adverse Events., and Table S9 in the Supplementary Appendix). Overall, 18 creatinine elevations (44%) remained in the normal range, and 36 (88%) were not confirmed on the next test. A total of 10 elevations led to discontinuation of a study drug (7 in the FTC–TDF group and 3 in the placebo group); study drugs were restarted in 9 subjects. Serum creatinine levels were elevated at more than one consecutive test in 5 subjects in the FTC–TDF group (<1%) and in none of the subjects in the placebo group. All elevations in the serum creatinine level resolved after the discontinuation of a study drug, within 4 weeks in 3 subjects, within 12 weeks in 1 subject, and within 20 weeks in 1 subject. Four of the subjects resumed taking FTC–TDF without recurrence of the elevation.Moderate nausea (grade 2 and above) was reported more frequently in the FTC–TDF group than in the placebo group (22 vs. 10 events, P=0.04), as was unintentional weight loss of 5% or more (34 vs. 19 events, P=0.04) (for details, see Table S10 in the Supplementary Appendix).
Effect of FTC–TDF on HIV Acquisition
HIV rapid testing was performed at 39,613 visits, during which there were false reactive tests for 3 subjects at 7 visits; each subject had multiple negative tests afterward. HIV seroconversion was observed in 110 persons, of whom 10 had plasma HIV RNA subsequently detected in specimens obtained at the enrollment visit. A finding of fewer than 40 copies per milliliter of plasma HIV RNA was documented for the other 100 HIV-infected subjects before seroconversion. Among the 100 subjects with emergent HIV infection, 36 occurred in the FTC–TDF group, and 64 occurred in the placebo group, representing a relative reduction of 44% in incidence in the modified intention-to-treat population (95% confidence interval [CI], 15 to 63; P=0.005) (Figure 2Figure 2
Kaplan–Meier Estimates of Time to HIV Infection (Modified Intention-to-Treat Population).). After adjustment for the difference in age between the two groups, the efficacy was 43% (95% CI, 14 to 62). The rate of pill use on 50% or more of days was recorded on the basis of pill counts, self-report, and dispensation records at 81% of visits on which efficacy was 50% (95% CI, 18 to 70; P=0.006). This rate did not differ significantly (P=0.48) from the efficacy at visits with less than 50% pill use of 32% (95% CI, −41 to 67%) (Figure 3Figure 3
HIV Incidence among Subjects Receiving FTC–TDF, According to Subgroup.). Efficacy of less than 30% could not be ruled out in the modified intention-to-treat analysis (P=0.15) or in the prespecified as-treated analysis at 50% pill use (P=0.09). There was no evidence of a change in HIV efficacy with longer follow-up (P=0.44).In prespecified analyses of efficacy according to subgroup, efficacy was higher among subjects who reported at screening that they had previously had unprotected receptive anal intercourse than among those who did not (efficacy, 58%; 95% CI, 32 to 74) (Figure 3). There was no significant between-group difference in protection on the basis of region, race or ethnic group, male circumcision, level of education, alcohol use, or age. In post hoc analyses, pill use on 90% or more of days was recorded at 49% of visits on which efficacy was 73% (95% CI, 41 to 88; P<0.001). Among all subjects, without exclusion for HIV infection at enrollment or the degree of compliance to the drug regimen, the efficacy was 47% (95% CI, 22 to 64; P=0.001).
Among the 10 subjects in whom plasma HIV RNA was subsequently detected in specimens obtained at enrollment, 5 had symptoms of an acute viral syndrome at enrollment, 2 had symptoms 1 week later (prompting an interim study visit), 1 had an anal sore, and 2 had leukopenia at enrollment. In these subjects, the clinicians did not suspect acute HIV infection, because the symptoms were attributed to an upper respiratory tract infection, sinusitis, or other non-HIV cause.
Of the preexisting HIV infections at enrollment, two occurred in the FTC–TDF group and eight in the placebo group (P=0.06). Among subjects who were infected after enrollment, the numbers with detectable plasma HIV RNA before seroconversion were 5 of 36 (14%) in the FTC–TDF group and 7 of 64 (11%) in the placebo group (P=0.75). The time to seroconversion after RNA detection was similar in the two groups (P=0.55). After the discontinuation of a study drug, seroconversion rates were similar among 320 subjects (161 in the FTC–TDF group and 159 in the placebo group) (P=0.42). These subjects had a total of 1173 visits for HIV testing after the discontinuation of a study drug (642 in the FTC–TDF group and 531 in the placebo group). During these visits, 5 seroconversions were observed (2 in the FTC–TDF group and 3 in the placebo group).
Drug-Level Detection and Prophylactic Effect
Among subjects who became infected with HIV, the median time between the tested specimen date and the last uninfected visit was 35 days (interquartile range, 28 to 56). No drug was detected in any plasma or cell specimens from subjects in the placebo group. Among subjects in the FTC–TDF group, at least one of the study-drug components was detected in 3 of 34 subjects with HIV infection (9%) and in 22 of 43 seronegative control subjects (51%) (Figure 4Figure 4
Levels of Study-Drug Components in Blood of Subjects Receiving FTC–TDF, According to HIV Status.). Of the 3 HIV-infected subjects with a detectable level of a study drug, none had cell-associated drug levels higher than the median for the 22 seronegative control subjects in whom a study-drug component was detected. Only 8% of subjects with HIV infection and 54% of control subjects who were considered “on treatment” on more than 50% of days had a detectable level of a study drug in plasma or peripheral-blood mononuclear cells (Table S8 in the Supplementary Appendix). Detection of the different drug components was more than 95% concordant (Table S6 in the Supplementary Appendix).In the FTC–TDF group, among subjects with a detectable study-drug level, as compared with those without a detectable level, the odds of HIV infection were lower by a factor of 12.9 (95% CI, 1.7 to 99.3; P<0.001), corresponding to a relative reduction in HIV risk of 92% (95% CI, 40 to 99; P<0.001). After adjustment for reported unprotected receptive anal intercourse, the relative risk reduction was 95% (95% CI, 70 to 99; P<0.001).
Effect of FTC–TDF on HIV Infection
Plasma HIV RNA levels and CD4+ T-cell counts were similar among subjects with seroconversion in the two groups (Figure S4 in the Supplementary Appendix). Among the 10 subjects who were infected at enrollment, 3 had FTC-resistant infections (2 of 2 in the FTC–TDF group and 1 of 8 in the placebo group) (Table S5 in the Supplementary Appendix). No TDF-resistant infections were observed. Among 36 subjects in the FTC–TDF group and 64 subjects in the placebo group who became infected with HIV during the trial, no FTC or TDF resistance was detected.
Discussion
Once-daily oral FTC–TDF provided 44% additional protection from HIV among men or transgender women who have sex with men who also received a comprehensive package of prevention services. The protective effect of FTC–TDF was significant but not as high as originally hypothesized during the design of the study. Although reported pill use was high, drug exposure that was measured objectively was substantially lower. The intracellular assay that was used in this study is expected to detect TFV-DP for 14 days or more after the last dose of TDF is taken (see Methods in the Supplementary Appendix). Other evidence of low drug exposure included the lack of drug resistance observed among emergent infections and the absence of suppression of the HIV RNA level in plasma at the seroconversion visit. There was no evidence of delayed seroconversion among subjects who were infected in the FTC–TDF group. More information will be available after the entire cohort stops receiving the study drug.
The estimate of biologic activity of FTC–TDF persists after adjustment for high-risk sexual practice, suggesting that the correlation between drug detection and protection is primarily due to the drug and not to other characteristics of subjects that may link poor adherence with higher risk. The testing of a larger number of specimens, from more subjects at more times, is needed to better define the minimum protective drug concentration. Protective drug levels may differ according to the type of exposure (rectal vs. penile). Drug level may have a role in monitoring trials, programs, and individual users. Methods for inexpensively measuring long-term drug exposure, such as that afforded by analysis of hair,19 would be helpful once such a method is fully validated.
Side effects may have contributed to low pill use among some subjects. As with treatment of HIV infection and the use of FTC–TDF in postexposure prophylaxis,20 the initiation of FTC–TDF preexposure prophylaxis was associated with self-limited start-up symptoms in a few subjects. The trial design involving a placebo may also have contributed to lower-than-expected pill use. All subjects were counseled that the study pill might be a placebo or an active drug having no proven benefit. Open-label research and program development could provide users with clearer information about expected benefits and risks, which might increase the use and efficacy of preexposure prophylaxis. Engagement with communities and additional behavioral research are needed to develop methods of counseling that better support such use.
The initiation of chemoprophylaxis either before or after exposure should be deferred in patients with signs or symptoms of a viral syndrome, which are often present during acute HIV infection.21,22 The initiation of postexposure prophylaxis in patients who are RNA-positive but antibody-negative has been linked with acquisition of resistance to FTC and lamivudine (3TC),5 as occurred in subjects in the FTC–TDF group who were already infected at enrollment in our trial. Ways to increase recognition of acute HIV infection would include routine measurement of body temperature and testing for HIV antibodies to evaluate viral syndromes, regardless of whether the presentation suggests HIV infection or another cause. Testing for HIV RNA at the time of the initiation of preexposure prophylaxis should be considered where available.
TDF treatment is known to cause decreases in renal function,23 and there were trends toward more creatinine elevations in the FTC–TDF group than in the placebo group. Most creatinine elevations were self-limited and were not confirmed on repeat testing of a new specimen, as might occur due to dehydration, creatine use, or exercise. The ability to detect safety outcomes, including drug resistance, may have been decreased by lower-than-expected drug exposure. In light of evidence of the efficacy of FTC–TDF, more information is needed about possible subclinical effects that may affect bone mineral density, low-level drug resistance, and proximal renal tubular function. Flares of hepatitis caused by HBV after stopping preexposure prophylaxis with TDF were not seen in West African women,12 but more information is needed. These issues are being investigated in existing trials of preexposure prophylaxis.
Reported high-risk behavior decreased substantially after enrollment and remained lower than at baseline during the trial. Safer behavior was also observed in a trial of preexposure prophylaxis with TDF in West African women12 and may reflect the services (e.g., counseling, testing, and dispensing of condoms) that are provided as part of such interventions. In addition, taking a pill a day may have served as a daily reminder of imminent risk and may have promoted planning for sex, which has been associated with lower HIV risk.24 Behavioral changes during future open-label use of preexposure prophylaxis may differ because of an increased expectation of benefits, although such “risk compensation” was not observed during an open-label study of postexposure prophylaxis, during which benefits were expected.25
The optimal regimen for preexposure prophylaxis has not been established, and data from the subjects in our study cannot be applied to other populations. Alternative regimens in different populations are being studied. (Details are available in the Discussion in the Supplementary Appendix and at www.avac.org.)
In our study, preexposure prophylaxis with oral FTC–TDF among men and transgender women who have sex with men addressed an important unmet need in public health. HIV prevalence is higher in this population than in other groups in almost all countries.14 In the United States, rates of HIV infection among such men and transgender women have climbed since the early 1990s, affecting in particular black and Hispanic subpopulations.26 Intensive counseling in behavioral risk reduction for such subjects has not been shown to be better than standard counseling.27 Although male circumcision partially protects heterosexual men,28-30 penile circumcision is not expected to protect those who are exposed on the rectal mucosa.31 Heterosexual women were partially protected by tenofovir 1% vaginal gel,13 but the safety and utility of tenofovir topical gels for rectal use is not yet known. In the FTC–TDF group, there was increased efficacy among subjects who reported having unprotected receptive anal intercourse, which is the main mode of HIV transmission among the subjects in our study and increases the risk of heterosexual women who engage in the practice.32 We showed that such subjects with a high risk of exposure to HIV can be mobilized to participate in prevention initiatives and that preexposure prophylaxis is effective for slowing the spread of HIV in this population.
Supported by the Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, as a cooperative agreement (UO1 AI64002, to Dr. Grant) and by the Bill and Melinda Gates Foundation. Study drugs were donated by Gilead Sciences. The pharmacological studies were sponsored by a cooperative agreement with DAIDS (UO1 AI84735, to Dr. Anderson). Support for some specimen handling came from a grant from DAIDS (RO1 AI062333, to Dr. Grant) and by the J. David Gladstone Institutes. Some infrastructure support at the University of California at San Francisco was provided by a grant from the National Institutes of Health (UL1 RR024131).
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
This article (10.1056/NEJMoa1011205) was published on November 23, 2010, and updated on December 1, 2010, at NEJM.org.
Dr. Grant reports receiving support as an advisor to Siemens (the manufacturer of TruGene HIV-1 Genotyping Kit); Dr. Mayer reports receiving grant support from Gilead, Merck, and Bristol-Myers Squibb; Dr. Kallás reports serving on a data and safety monitoring board for Merck; Dr. Schechter reports receiving consulting fees and grants from Gilead; Drs. Liu and Anderson report receiving donations of study drug from Gilead for various PrEP projects; and Drs. Jaffe and Rooney report being employees of Gilead Sciences and owning stock in the company. No other potential conflict of interest relevant to this article was reported.
We thank the study subjects for their dedication to finding new ways to protect communities and for their trust in us; the community advisory boards; the members of the DAIDS multinational independent data and safety monitoring board, Kathy Edwards (chair), Shrikant I. Bangdiwala, KyungMann Kim, W.D. Francois Venter, Alejandro Llanos-Cuentas, Olavo Henrique Munhoz Leite, V.I. Mathan, Carlos Seas, Panpit Suwangool, Wafaa El-Sadr, Gary Maartens, Gabriel Thimonthe, Michael Proschan, and Dennis Dixon; community advocates Mitchell Warren, Julie Davids, Susana Chavez, Jorge (Tito) Bracamonte, and Carlos Caceres; Caitlin Fernandez, Joseph Rower, and Brandon Klein for their analytical pharmacology assistance; Grace Chow and Stephen Becker for their guidance as project officers; John Carroll of the Gladstone Institutes for providing original versions of the figures; Miguel Bernal and Ximena Barra for their print and film work; Mark Aurigemma for developing communication materials; Malu Robles for her assistance in the preparation of the manuscript; and Mark Wainberg, Mike Youle, Sandra Lehrman, Jose Pilotto, Neptali Arias, Vivian Levy, Kimberly Page, and Renee Ridzon for inspiration and logistical work.
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. Grant at the J. David Gladstone Institutes, University of California at San Francisco, 1650 Owens St., San Francisco, CA, 94158, or at robert.grant@ucsf.edu.
Other members of the Preexposure Prophylaxis Initiative (iPrEx) study team are listed in the Supplementary Appendix, available at NEJM.org.
Appendix
The authors' affiliations are as follows: the Gladstone Institute of Virology and Immunology (R.M.G., V.M., P.G., R.J.H., J.J.M., P.D., J.L.), the University of California, San Francisco (R.M.G., A.Y.L., S.P.B., K.M., F.W., D.V.G.), and the HIV Research Section, San Francisco Department of Public Health (A.Y.L., S.P.B.) — all in San Francisco; Investigaciones Medicas en Salud, Lima (J.R.L., L.V.), Asociación Civil Impacta Salud y Educación, Lima (J.R.L., J.V.G.-C., M.E.R.-C., C.G.), and Asociación Civil Selva Amazónica, Iquitos (M.C.) — all in Peru; the University of Colorado, Denver (P.L.A., L.R.B., J.-H.Z.).; Fundación Ecuatoriana Equidad, Guayaquil, Ecuador (O.M.-H., T.F.); Instituto de Pesquisa Clinica Evandro Chagas–Fundação Oswaldo Cruz (V.G.V.), and Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro (M.S.) — both in Rio de Janeiro; Brown University, Providence, RI (K.H.M.); the Fenway Institute, Fenway Health, Boston (K.H.M.); the Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, and Instituto de Investigação em Imunologia — both in São Paulo (E.G.K.); Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand (S.C.); Desmond Tutu HIV Centre and Department of Medicine, University of Cape Town, Cape Town, South Africa (L.-G.B.); Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (A.I.M., D.N.B.); Gilead Sciences, Foster City, CA ( J.F.R., H.S.J.); DF/Net Research, Seattle (B.P.); Applied Health Research, Brighton, MI (K.R.A.); and the Center for Health, Intervention, and Prevention, University of Connecticut, Storrs (K.R.A.).
- References
References
1
Donnell D ,Baeten JM ,Kiarie J , et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375:2092-2098
CrossRef | Web of Science | Medline2
Connor EM ,Sperling RS ,Gelber R , et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-1180
Free Full Text | Web of Science | Medline3
Smith DK ,Grohskopf LA ,Black RJ , et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005;54:1-20
Medline4
Schechter M ,do Lago RF ,Mendelsohn AB ,Moreira RI ,Moulton LH ,Harrison LH . Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004;35:519-525
CrossRef | Web of Science | Medline5
Roland ME ,Neilands TB ,Krone MR , et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41:1507-1513
CrossRef | Web of Science | Medline6
Grant RM ,Buchbinder S ,Cates W Jr , et al. AIDS: promote HIV chemoprophylaxis research, don't prevent it. Science 2005;309:2170-2171
CrossRef | Web of Science | Medline7
Denton PW ,Estes JD ,Sun Z , et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5:e16-e16
CrossRef | Web of Science | Medline8
Tsai C-C ,Follis KE ,Sabo A , et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1199
CrossRef | Web of Science | Medline9
Van Rompay KKA ,McChesney MB ,Aguirre NL ,Schmidt KA ,Bischofberger N ,Marthas ML . Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184:429-438
CrossRef | Web of Science | Medline10
Garcia-Lerma JG ,Otten RA ,Qari SH , et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5:e28-e28
CrossRef | Web of Science | Medline11
Garcia-Lerma JG ,Cong ME ,Mitchell J , et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010;2:14ra4-14ra4
CrossRef | Web of Science12
Peterson L ,Taylor D ,Roddy R , et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2:e27-e27
CrossRef | Medline13
Abdool Karim Q ,Abdool Karim SS ,Frohlich JA , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174
CrossRef | Web of Science | Medline14
van Griensven F , de Lind van Wijngaarden JW,Baral S ,Grulich A . The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009;4:300-307
CrossRef | Web of Science15
Beyrer C ,Baral SD ,Walker D ,Wirtz AL ,Johns B ,Sifakis F . The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidemiol Rev 2010;32:137-151
CrossRef | Web of Science | Medline16
Liu AY ,Kittredge PV ,Vittinghoff E , et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008;47:241-247
CrossRef | Web of Science | Medline17
Mimiaga MJ ,Case P ,Johnson CV ,Safren SA ,Mayer KH . Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009;50:77-83
CrossRef | Web of Science | Medline18
Good participatory practice: guidelines for biomedical HIV prevention trials. Geneva: UNAIDS, 2007.
19
Liu A, Vittinghoff E, Gandhi M, et al. Validating measures of tenofovir drug exposure in a US pre-exposure prophylaxis trial. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 27–March 2, 2010.
20
Mayer KH ,Mimiaga MJ ,Cohen D , et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center. J Acquir Immune Defic Syndr 2008;47:494-499
CrossRef | Web of Science | Medline21
Schacker TW ,Hughes JP ,Shea T ,Coombs RW ,Corey L . Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-620
Web of Science | Medline22
Hofer CB ,Harrison LH ,Struchiner CJ , et al. Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. J Acquir Immune Defic Syndr 2000;25:188-191
CrossRef | Web of Science | Medline23
Gallant JE ,Winston JA ,DeJesus E , et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008;22:2155-2163
CrossRef | Web of Science | Medline24
van Griensven F ,Thienkrua W ,Sukwicha W , et al. Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection. J Int AIDS Soc 2010;13:13-13
CrossRef | Web of Science25
Martin JN ,Roland ME ,Neilands TB , et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-792
CrossRef | Web of Science | Medline26
Hall HI ,Song R ,Rhodes P , et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-529
CrossRef | Web of Science | Medline27
Koblin B ,Chesney M ,Coates T . Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 2004;364:41-50
CrossRef | Web of Science | Medline28
Auvert B ,Taljaard D ,Lagarde E ,Sobngwi-Tambekou J ,Sitta R ,Puren A . Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298-e298[Erratum, PLoS Med 2006;3(5):e226.]
CrossRef | Web of Science | Medline29
Bailey RC ,Moses S ,Parker CB , et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-656
CrossRef | Web of Science | Medline30
Gray RH ,Kigozi G ,Serwadda D , et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657-666
CrossRef | Web of Science | Medline31
Templeton DJ ,Millett GA ,Grulich AE . Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Curr Opin Infect Dis 2010;23:45-52
CrossRef | Web of Science | Medline32
Baggaley RF ,White RG ,Boily MC . HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010;39:1048-1063
CrossRef | Web of Science | Medline
- Citing Articles (431)
Citing Articles
1
U. L. Abbas, R. Glaubius, A. Mubayi, G. Hood, J. W. Mellors. (2013) Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV Transmission and Drug Resistance in South Africa. Journal of Infectious Diseases 208:2, 224-234
2
C. Celum, T. B. Hallett, J. M. Baeten. (2013) HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact. Journal of Infectious Diseases 208:2, 189-191
3
Katherine B. Rucinski, Nana P. Mensah, Kent A. Sepkowitz, Blayne H. Cutler, M. Monica Sweeney, Julie E. Myers. (2013) Knowledge and Use of Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in New York City. AIDS and Behavior 17:6, 2180-2184
4
Brian Mustanski, Amy K. Johnson, Robert Garofalo, Daniel Ryan, Michelle Birkett. (2013) Perceived Likelihood of Using HIV Pre-exposure Prophylaxis Medications Among Young Men Who Have Sex with Men. AIDS and Behavior 17:6, 2173-2179
5
K. Rivet Amico, Leila E. Mansoor, Amy Corneli, Kristine Torjesen, Ariane Straten. (2013) Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials. AIDS and Behavior 17:6, 2143-2155
6
Martin Holt, Dean Murphy, Denton Callander, Jeanne Ellard, Marsha Rosengarten, Susan Kippax, John Wit. (2013) HIV-Negative and HIV-Positive Gay Men’s Attitudes to Medicines, HIV Treatments and Antiretroviral-based Prevention. AIDS and Behavior 17:6, 2156-2161
7
Elisabeth Maria Elst, Judie Mbogua, Don Operario, Gaudensia Mutua, Caroline Kuo, Peter Mugo, Jennifer Kanungi, Sagri Singh, Jessica Haberer, Frances Priddy, Eduard Joachim Sanders. (2013) High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya. AIDS and Behavior 17:6, 2162-2172
8
Jonathan D. Fuchs, Magdalena E. Sobieszczyk, Tamra Madenwald, Doug Grove, Shelly T. Karuna, Michele Andrasik, Adam Sherwat, Gail Broder, Kenneth Mayer, Beryl Koblin, Scott Hammer. (2013) Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants. JAIDS Journal of Acquired Immune Deficiency Syndromes 63:3, 259-262
9
Jeremy Sugarman, Kenneth H. Mayer. (2013) Ethics and Pre-exposure Prophylaxis for HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S135-S139
10
Jared M. Baeten, Jessica E. Haberer, Albert Y. Liu, Nirupama Sista. (2013) Preexposure Prophylaxis for HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S122-S129
11
Beryl A. Koblin, Michele Andrasik, Judy Austin. (2013) Preparing for the Unexpected. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S183-S186
12
Bluma G. Brenner, Mark A. Wainberg. (2013) Future of Phylogeny in HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S248-S254
13
Sten H. Vermund, Sarah J. Fidler, Helen Ayles, Nulda Beyers, Richard J. Hayes. (2013) Can Combination Prevention Strategies Reduce HIV Transmission in Generalized Epidemic Settings in Africa? The HPTN 071 (PopART) Study Plan in South Africa and Zambia. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S221-S227
14
Kenneth H. Mayer, Darrell P. Wheeler, Linda-Gail Bekker, Beatriz Grinsztejn, Robert H. Remien, Theodorus G. M. Sandfort, Chris Beyrer. (2013) Overcoming Biological, Behavioral, and Structural Vulnerabilities. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S161-S167
15
Connie Celum, Jared M. Baeten, James P. Hughes, Ruanne Barnabas, Albert Liu, Heidi Van Rooyen, Susan Buchbinder. (2013) Integrated Strategies for Combination HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S213-S220
16
Steve Shoptaw, Brooke Montgomery, Chyvette T. Williams, Nabila El-Bassel, Apinun Aramrattana, Lisa Metsch, David S. Metzger, Irene Kuo, Francisco I. Bastos, Steffanie A. Strathdee. (2013) Not Just the Needle. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S174-S178
17
Audrey Pettifor, Linda-Gail Bekker, Sybil Hosek, Ralph DiClemente, Molly Rosenberg, Sheana S. Bull, Susannah Allison, Sinead Delany-Moretlwe, Bill G. Kapogiannis, Frances Cowan. (2013) Preventing HIV Among Young People. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S155-S160
18
Hong-Van Tieu, Morgane Rolland, Scott M. Hammer, Magdalena E. Sobieszczyk. (2013) Translational Research Insights From Completed HIV Vaccine Efficacy Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S150-S154
19
Wafaa M. El-Sadr, David M. Serwadda, Nirupama Sista, Myron S. Cohen. (2013) HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S115-S116
20
Mitchell J. Warren, Emily S. Bass. (2013) Perspectives on HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S255-S259
21
Deborah Donnell, James P. Hughes, Lei Wang, Ying Q. Chen, Thomas R. Fleming. (2013) Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S130-S134
22
Corbin G. Thompson, Myron S. Cohen, Angela D.M. Kashuba. (2013) Antiretroviral Pharmacology in Mucosal Tissues. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S240-S247
23
Margaret L. McNairy, Andrea A. Howard, Wafaa M. El-Sadr. (2013) Antiretroviral Therapy for Prevention of HIV and Tuberculosis. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S200-S207
24
R. K. Gupta, M. A. Wainberg, F. Brun-Vezinet, J. M. Gatell, J. Albert, A. Sonnerborg, J. B. Nachega. (2013) Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. Journal of Infectious Diseases 207:suppl 2, S101-S106
25
H. Gatanaga, T. Hayashida, J. Tanuma, S. Oka. (2013) Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. Clinical Infectious Diseases 56:12, 1812-1819
26
A. B. Jena. (2013) Editorial Commentary: Balancing Disease Eradication With the Emergence of Multidrug-Resistant HIV in Test-and-Treat Policies. Clinical Infectious Diseases 56:12, 1797-1799
27
E. Rosenthal, L. Piroth, E. Cua, A. Joulié, I. Ravaux, M. Chauveau, K. Lacombe, L. Cotte, P. Bonnard, L. Weiss, M. Longuet, C. Pradier, P. Cacoub, . (2013) Preexposure prophylaxis (PrEP) of HIV infection in France: A nationwide cross-sectional study (PREVIC study). AIDS Care1-10
28
Piot , Peter , Quinn , Thomas C. , . (2013) Response to the AIDS Pandemic — A Global Health Model. New England Journal of Medicine 368:23, 2210-2218
Free Full Text29
Heather Senn, James Wilton, Malika Sharma, Shawn Fowler, Darrell Tan. (2013) Knowledge of and opinions on HIV pre-exposure prophylaxis among front-line service providers at Canadian AIDS Service Organizations. AIDS Research and Human Retroviruses130603195728009
30
Sten H. Vermund, Richard J. Hayes. (2013) Combination Prevention: New Hope for Stopping the Epidemic. Current HIV/AIDS Reports 10:2, 169-186
31
Jared M. Baeten, Robert Grant. (2013) Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?. Current HIV/AIDS Reports 10:2, 142-151
32
Margaret L. McNairy, Myron Cohen, Wafaa M. El-Sadr. (2013) Antiretroviral Therapy for Prevention Is a Combination Strategy. Current HIV/AIDS Reports 10:2, 152-158
33
Peter Cherutich, Rebecca Bunnell, Jonathan Mermin. (2013) HIV Testing: Current Practice and Future Directions. Current HIV/AIDS Reports 10:2, 134-141
34
Susan Kasedde, Chewe Luo, Craig McClure, Upjeet Chandan. (2013) Reducing HIV and AIDS in Adolescents: Opportunities and Challenges. Current HIV/AIDS Reports 10:2, 159-168
35
J. E. Myers, K. A. Sepkowitz. (2013) A Pill for HIV Prevention: Deja Vu All Over Again?. Clinical Infectious Diseases 56:11, 1604-1612
36
Gina M. Wingood, Kristin Dunkle, Christina Camp, Shilpa Patel, Julia E. Painter, Anna Rubtsova, Ralph J. DiClemente. (2013) Racial Differences and Correlates of Potential Adoption of Preexposure Prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S95-S101
37
Sten H. Vermund, José A. Tique, Holly M. Cassell, Megan E. Pask, Philip J. Ciampa, Carolyn M. Audet. (2013) Translation of Biomedical Prevention Strategies for HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S12-S25
38
Dianne M. Rausch, Cynthia I. Grossman, Emily J. Erbelding. (2013) Integrating Behavioral and Biomedical Research in HIV Interventions. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S6-S11
39
John F. Murray. (2013) Epidemiology of Human Immunodeficiency Virus–Associated Pulmonary Disease. Clinics in Chest Medicine 34:2, 165-179
40
Conall O’Cleirigh, Michael E. Newcomb, Kenneth H. Mayer, Margie Skeer, Lara Traeger, Steven A. Safren. (2013) Moderate Levels of Depression Predict Sexual Transmission Risk in HIV-Infected MSM: A Longitudinal Analysis of Data From Six Sites Involved in a “Prevention for Positives” Study. AIDS and Behavior 17:5, 1764-1769
41
Bridget Haire, Morenike Oluwatoyin Folayan, Catherine Hankins, Jeremy Sugarman, Sheena McCormack, Gita Ramjee, Mitchell Warren. (2013) Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining P
r EP. Developing World Bioethicsn/a-n/a42
Stuart Rennie. (2013) Ethical Use of Antiretroviral Resources for HIV Prevention in Resource Poor Settings. Developing World Bioethicsn/a-n/a
43
Kachit Choopanya, Michael Martin, Pravan Suntharasamai, Udomsak Sangkum, Philip A Mock, Manoj Leethochawalit, Sithisat Chiamwongpaet, Praphan Kitisin, Pitinan Natrujirote, Somyot Kittimunkong, Rutt Chuachoowong, Roman J Gvetadze, Janet M McNicholl, Lynn A Paxton, Marcel E Curlin, Craig W Hendrix, Suphak Vanichseni. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet
44
Nicolette A. Louissaint, Ying-Jun Cao, Paul L. Skipper, Rosa G. Liberman, Steven R. Tannenbaum, Sridhar Nimmagadda, Jean R. Anderson, Stephanie Everts, Rahul Bakshi, Edward J. Fuchs, Craig W. Hendrix. (2013) Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. AIDS Research and Human Retroviruses130529065246001
45
Hyman M. Scott, Vincent Fuqua, H. Fisher Raymond. (2013) Utilization of HIV Prevention Services Across Racial/Ethnic Groups Among Men Who Have Sex with Men in San Francisco, California, 2008. AIDS and Behavior
46
Lindsay B. Avery, Melissa A. Zarr, Rahul P. Bakshi, Robert F. Siliciano, Craig W. Hendrix. (2013) Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. AIDS Research and Human Retroviruses130522065303009
47
Joseph Romano, Angela Kashuba, Stephen Becker, James Cummins, Jim Turpin, Fulvia Veronese, on Behalf of the Antiretr. (2013) Pharmacokinetics and Pharmacodynamics in HIV Prevention: Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention. AIDS Research and Human Retroviruses130522065303009
48
, Panagiotis Vagenas, Kaysia T. Ludford, Pedro Gonzales, Jesus Peinado, Cesar Cabezas, Fernando Gonzales, Javier R. Lama, Jorge Sanchez, Frederick L. Altice. (2013) Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. AIDS and Behavior
49
Kristina Rodriguez, Delivette Castor, Timothy L. Mah, Stephanie H. Cook, Lex M. Auguiste, Perry N. Halkitis, Marty Markowitz. (2013) Participation in research involving novel sampling and study designs to identify acute HIV-1 infection among minority men who have sex with men. AIDS Care 25:7, 828-834
50
Lisa A. Eaton, Seth C. Kalichman, David A. Kenny, Ofer Harel. (2013) A reanalysis of a behavioral intervention to prevent incident HIV infections: Including indirect effects in modeling outcomes of Project EXPLORE. AIDS Care 25:7, 805-811
51
Kaja-Triin Laisaar, Anneli Uusküla, Anjali Sharma, Jack A. DeHovitz, K. Rivet Amico. (2013) Developing an adherence support intervention for patients on antiretroviral therapy in the context of the recent IDU-driven HIV/AIDS epidemic in Estonia. AIDS Care 25:7, 863-873
52
Sung-Jae Lee, Ronald Brooks, Robert K. Bolan, Risa Flynn. (2013) Assessing willingness to test for HIV among men who have sex with men using conjoint analysis, evidence for uptake of the FDA-approved at-home HIV test. AIDS Care1-7
53
Deborah Mindry, Glenn Wagner, Jordan Lake, Amber Smith, Sebastian Linnemayr, Molly Quinn, Risa Hoffman. (2013) Fertility Desires Among HIV-Infected Men and Women in Los Angeles County: Client Needs and Provider Perspectives. Maternal and Child Health Journal 17:4, 593-600
54
Stefan Baral, Andrew Scheibe, Patrick Sullivan, Gift Trapence, Andrew Lambert, Linda-Gail Bekker, Chris Beyrer. (2013) Assessing Priorities for Combination HIV Prevention Research for Men Who have Sex with Men (MSM) in Africa. AIDS and Behavior 17:S1, 60-69
55
Enrique Vacas Córdoba, Eduardo Arnaiz, Miguel Relloso, Carlos Sánchez-Torres, Federico García, Lucía Pérez-Álvarez, Rafael Gómez, Francisco J. de la Mata, Marjorie Pion, Ma Ángeles Muñoz-Fernández. (2013) Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. AIDS 27:8, 1219-1229
56
Darrel H. Higa, Nicole Crepaz, Khiya J. Marshall, Linda Kay, H. Waverly Vosburgh, Pilgrim Spikes, Cynthia M. Lyles, David W. Purcell. (2013) A Systematic Review to Identify Challenges of Demonstrating Efficacy of HIV Behavioral Interventions for Gay, Bisexual, and Other Men Who Have Sex with Men (MSM). AIDS and Behavior 17:4, 1231-1244
57
Faiza Yasin, Altanchimeg Delegchoimbol, Naranchimeg Jamiyanjamts, Tugsdelger Sovd, Krystal Mason, Stefan Baral. (2013) A Cross-Sectional Evaluation of Correlates of HIV Testing Practices Among Men Who Have Sex with Men (MSM) in Mongolia. AIDS and Behavior 17:4, 1378-1385
58
, Douglas Bruce, Gary W. Harper, Katie Suleta. (2013) Sexual Risk Behavior and Risk Reduction Beliefs Among HIV-Positive Young Men Who have Sex with Men. AIDS and Behavior 17:4, 1515-1523
59
Garrett Prestage, Graham Brown, Ian Alan Down, Fengyi Jin, Michael Hurley. (2013) “It’s Hard to Know What is a Risky or not a Risky Decision”: Gay Men’s Beliefs About Risk During Sex. AIDS and Behavior 17:4, 1352-1361
60
Yea-Hung Chen, H. Fisher Raymond, Michael Grasso, Binh Nguyen, Tyler Robertson, Willi McFarland. (2013) Prevalence and Predictors of Conscious Risk Behavior Among San Franciscan Men who have Sex with Men. AIDS and Behavior 17:4, 1338-1343
61
Aimee N. C. Campbell, Susan Tross, Donald A. Calsyn. (2013) Substance Use Disorders and HIV/AIDS Prevention and Treatment Intervention: Research and Practice Considerations. Social Work in Public Health 28:3-4, 333-348
62
Annemarie Shibata, Emily McMullen, Alex Pham, Michael Belshan, Bridget Sanford, You Zhou, Michael Goede, Abhijit A. Date, Christopher J. Destache. (2013) Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment. AIDS Research and Human Retroviruses 29:5, 746-754
63
M.-e. Cong, J. Mitchell, E. Sweeney, S. Bachman, D. L. Hanson, W. Heneine, J. G. Garcia-Lerma. (2013) Prophylactic Efficacy of Oral Emtricitabine and Tenofovir Disoproxil Fumarate Combination Therapy Against a Tenofovir-Resistant Simian/Human Immunodeficiency Virus Containing the K65R Mutation in Macaques. Journal of Infectious Diseases
64
Lindsay B Avery, Melissa A Zarr, Rahul P. Bakshi, Robert F Siliciano, Craig W. Hendrix. (2013) Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. AIDS Research and Human Retroviruses130422030601002
65
Nicolette A Louissaint, Ying-Jun Cao, Paul L Skipper, Rosa G. Liberman, Steven R. Tannenbaum, Sridhar Nimmagadda, Jean R. Anderson, Stephanie Everts, Rahul P. Bakshi, Edward J. Fuchs, Craig Hendrix. (2013) Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic and Vaginal Tissue. AIDS Research and Human Retroviruses130422031400000
66
Jessica M. Conway, Bernhard P. Konrad, Daniel Coombs. (2013) Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection. SIAM Journal on Applied Mathematics 73:2, 904-928
67
L. Kuhn, H.-Y. Kim, J. Walter, D. M. Thea, M. Sinkala, M. Mwiya, C. Kankasa, D. Decker, G. M. Aldrovandi. (2013) HIV-1 Concentrations in Human Breast Milk Before and After Weaning. Science Translational Medicine 5:181, 181ra51-181ra51
68
Elisa F. Long, Robert R. Stavert. (2013) Portfolios of Biomedical HIV Interventions in South Africa: A Cost-Effectiveness Analysis. Journal of General Internal Medicine
69
J. E. Pace, G. K. Siberry, R. Hazra, B. G. Kapogiannis. (2013) Preexposure Prophylaxis for Adolescents and Young Adults at Risk for HIV Infection: Is an Ounce of Prevention Worth a Pound of Cure?. Clinical Infectious Diseases 56:8, 1149-1155
70
K. H. Mayer, B. C. Zanoni. (2013) Editorial Commentary: HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet. Clinical Infectious Diseases 56:8, 1156-1158
71
S. Rerks-Ngarm, R. M. Paris, S. Chunsutthiwat, N. Premsri, C. Namwat, C. Bowonwatanuwong, S. S. Li, J. Kaewkungkal, R. Trichavaroj, N. Churikanont, M. S. de Souza, C. Andrews, D. Francis, E. Adams, J. Flores, S. Gurunathan, J. Tartaglia, R. J. O'Connell, C. Eamsila, S. Nitayaphan, V. Ngauy, P. Thongcharoen, P. Kunasol, N. L. Michael, M. L. Robb, P. B. Gilbert, J. H. Kim. (2013) Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. Journal of Infectious Diseases 207:8, 1195-1205
72
Sybil G. Hosek, George Siberry, Margo Bell, Michelle Lally, Bill Kapogiannis, Keith Green, M. Isabel Fernandez, Brandy Rutledge, Jaime Martinez, Robert Garofalo, Craig M. Wilson. (2013) The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:4, 447-456
73
Paige Etter, Raphael Landovitz, Sengeziwe Sibeko, Magdalena E. Sobieszczyk, Sharon A. Riddler, Carissa Karg, Athe Tsibris, Jeffrey Schouten. (2013) Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS 27:7, 1119-1128
74
Bluma Brenner, Mark A. Wainberg, Michel Roger. (2013) Phylogenetic inferences on HIV-1 transmission. AIDS 27:7, 1045-1057
75
Lori A. Nacius, Judy Levison, Charles G. Minard, Carl Fasser, Jessica A. Davila. (2013) Serodiscordance and Disclosure Among HIV-Positive Pregnant Women in the Southwestern United States. AIDS Patient Care and STDs 27:4, 242-247
76
Sarit A. Golub, Kristi E. Gamarel, H. Jonathon Rendina, Anthony Surace, Corina L. Lelutiu-Weinberger. (2013) From Efficacy to Effectiveness: Facilitators and Barriers to PrEP Acceptability and Motivations for Adherence Among MSM and Transgender Women in New York City. AIDS Patient Care and STDs 27:4, 248-254
77
Erik De Clercq. (2013) The Acyclic Nucleoside Phosphonates (ANPs): Antonín Holý's Legacy. Medicinal Research Reviewsn/a-n/a
78
Emma Torres, Jean-Luc Meynard. (2013) Zoom sur la prophylaxie préexposition. La Revue de l'Infirmière 62:190, 28
79
Bridget Haire, John M. Kaldor. (2013) Ethics of ARV Based Prevention: Treatment-as-Prevention and PrEP. Developing World Bioethicsn/a-n/a
80
Virginie Supervie. (2013) Les moyens de prévention de l’infection à VIH à base d’antirétroviraux. médecine/sciences 29:4, 373-382
81
Jean-François Delfraissy. (2013) Quels enjeux de recherche trente ans après l’identification du virus VIH ?. médecine/sciences 29:4, 339-340
82
G.E. Gray, B. Metch, G. Churchyard, K. Mlisana, M. Nchabeleng, M. Allen, Z. Moodie, J. Kublin, L.-G. Bekker. (2013) Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?. Vaccine 31:16, 2089-2096
83
Bridget Haire, Christopher Jordens. (2013) Standard of Prevention in the Real World: A qualitative Study of Principal Investigators in HIV Biomedical Prevention Trials. AJOB Primary Research130313084509005
84
Richard A. Crosby. (2013) State of Condom Use in HIV Prevention Science and Practice. Current HIV/AIDS Reports 10:1, 59-64
85
Allan R. Tenorio, Alan L. Landay. (2013) HIV: So Near and Yet So Far. Current HIV/AIDS Reports 10:1, 1-2
86
Ariane Straten, Elizabeth T. Montgomery, Miriam Hartmann, Alexandra Minnis. (2013) Methodological Lessons from Clinical Trials and the Future of Microbicide Research. Current HIV/AIDS Reports 10:1, 89-102
87
Jessica L. Adams, Craig Sykes, Prema Menezes, Heather M.A. Prince, Kristine B. Patterson, Katrien Fransen, Tania Crucitti, Irith De Baetselier, Lut Van Damme, Angela D.M. Kashuba. (2013) Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared With Isolated Peripheral Blood Mononuclear Cells. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:3, 260-266
88
Iryna B. Zablotska, Garrett Prestage, John de Wit, Andrew E. Grulich, Limin Mao, Martin Holt. (2013) The Informal Use of Antiretrovirals for Preexposure Prophylaxis of HIV Infection Among Gay Men in Australia. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:3, 334-338
89
Susan A. Adakun, Mark J. Siedner, Conrad Muzoora, Jessica E. Haberer, Alexander C. Tsai, Peter W. Hunt, Jeff N. Martin, David R. Bangsberg. (2013) Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:3, 317-321
90
Akil Jackson, Graeme Moyle, Victoria Watson, John Tjia, Alieu Ammara, David Back, Malika Mohabeer, Brian Gazzard, Marta Boffito. (2013) Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:3, 275-281
91
W. Kromdijk, S.A. Pereira, H. Rosing, J.W. Mulder, J.H. Beijnen, A.D.R. Huitema. (2013) Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B 919-920, 43-51
92
V. Savasi, L. Mandia, A. Laoreti, I. Cetin. (2013) Reproductive assistance in HIV serodiscordant couples. Human Reproduction Update 19:2, 136-150
93
Frits van Griensven, Warunee Thienkrua, Janet McNicholl, Wipas Wimonsate, Supaporn Chaikummao, Wannee Chonwattana, Anchalee Varangrat, Pachara Sirivongrangson, Philip A. Mock, Pasakorn Akarasewi, Jordan W. Tappero. (2013) Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand. AIDS 27:5, 825-832
94
Stephanie L. Combes, Asfawesen G-Yohannes, Altaye Kidane, Pai-Lien Chen, Abraham Aseffa, Paul J. Feldblum, Dominick Shattuck. (2013) HIV Prevalence and Incidence Among Women at Higher Risk of Infection in Addis Ababa, Ethiopia. AIDS Research and Human Retroviruses 29:3, 535-540
95
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba. (2013) HIV pre-exposure prophylaxis trials: the road to success. Clinical Investigation 3:3, 295-308
96
Greg L. Plosker. (2013) Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis. Drugs 73:3, 279-291
97
Shu-Hsing Cheng, Chin-Hui Yang, Yu-Mei Hsueh. (2013) Highly Active Antiretroviral Therapy is Associated with Decreased Incidence of Sexually Transmitted Diseases in a Taiwanese HIV-Positive Population. AIDS Patient Care and STDs 27:3, 155-162
98
Yan Zhang, Bin Peng, Ying She, Hao Liang, Hong-Bin Peng, Han-Zhu Qian, Sten H. Vermund, Xiao-Ni Zhong, Ailong Huang. (2013) Attitudes Toward HIV Pre-Exposure Prophylaxis Among Men Who Have Sex with Men in Western China. AIDS Patient Care and STDs 27:3, 137-141
99
Stefan D Baral, Tonia Poteat, Susanne Strömdahl, Andrea L Wirtz, Thomas E Guadamuz, Chris Beyrer. (2013) Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. The Lancet Infectious Diseases 13:3, 214-222
100
Kristen Underhill. (2013) Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and research ethics. Social Science & Medicine
101
Yuqin Zhao, Dobromir T. Dimitrov, Hao Liu, Yang Kuang. (2013) Mathematical Insights in Evaluating State Dependent Effectiveness of HIV Prevention Interventions. Bulletin of Mathematical Biology
102
Timothy Frasca, Gary W. Dowsett, Alex Carballo-Diéguez. (2013) The ethics of barebacking: Implications of gay men's concepts of right and wrong in the context of HIV. International Journal of Sexual Health130206090536008
103
P Flowers, C Knussen, J Li, L McDaid. (2013) Has testing been normalized? An analysis of changes in barriers to HIV testing among men who have sex with men between 2000 and 2010 in Scotland, UK. HIV Medicine 14:2, 92-98
104
Iván C. Balán, Alex Carballo-Diéguez, Ana Ventuneac, Robert H. Remien, Curtis Dolezal, Jordan Ford. (2013) Are HIV-Negative Men Who Have Sex with Men and Who Bareback Concerned About HIV Infection? Implications for HIV Risk Reduction Interventions. Archives of Sexual Behavior 42:2, 279-289
105
Beatrice “Bean” E. Robinson, Jennifer S. Galbraith, Rebecca E. Swinburne Romine, Qing Zhang, Jeffrey H. Herbst. (2013) Differences Between HIV-Positive and HIV-Negative African American Men Who Have Sex with Men in Two Major U.S. Metropolitan Areas. Archives of Sexual Behavior 42:2, 267-278
106
Preston Izulla, Lyle R. McKinnon, Julius Munyao, Sarah Karanja, Winnie Koima, Joshua Parmeres, Solomon Kamuti, Rosalia Kioko, Nico Nagelkerke, Gloria Gakii, Charles Wachihi, Nicholas Muraguri, Helgar Musyoki, Lawrence Gelmon, Rupert Kaul, Joshua Kimani. (2013) HIV Postexposure Prophylaxis in an Urban Population of Female Sex Workers in Nairobi, Kenya. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:2, 220-225
107
Pamina M. Gorbach, Barbara S. Mensch, Marla Husnik, Astou Coly, Benoit Mâsse, Bonus Makanani, Chiwawa Nkhoma, Lameck Chinula, Tchangani Tembo, Stan Mierzwa, Kimberly Reynolds, Stacey Hurst, Anne Coletti, Andrew Forsyth. (2013) Effect of Computer-Assisted Interviewing on Self-Reported Sexual Behavior Data in a Microbicide Clinical Trial. AIDS and Behavior 17:2, 790-800
108
Deborah J. Donnell, Jared M. Baeten, Ting Hong, Jairam R. Lingappa, Andrew Mujugira, Edith Nakku-Joloba, David Bangsberg, Connie Celum. (2013) Correlation Between Pill Counts and Biologic Effects in an HIV-1 Prevention Clinical Trial: Implications for Measuring Adherence. AIDS and Behavior 17:2, 632-639
109
Barbara S. Mensch, Barbara A. Friedland, Sharon A. Abbott, Lauren L. Katzen, Waimar Tun, Christine A. Kelly, Avina Sarna, Aylur K. Srikrishnan, Suniti Solomon. (2013) Characteristics of Female Sex Workers in Southern India Willing and Unwilling to Participate in a Placebo Gel Trial. AIDS and Behavior 17:2, 585-597
110
Lynn T. Matthews, Tamaryn Crankshaw, Janet Giddy, Angela Kaida, Jennifer A. Smit, Norma C. Ware, David R. Bangsberg. (2013) Reproductive Decision-Making and Periconception Practices Among HIV-Positive Men and Women Attending HIV Services in Durban, South Africa. AIDS and Behavior 17:2, 461-470
111
Sengeziwe Sibeko, Shokouh Makvandi-Nejad. (2013) From the Laboratory to Clinical Trials and Back Again: Lessons Learned from HIV Prevention Trials. American Journal of Reproductive Immunology 69, 106-115
112
Susan M. Fetherston, Peter Boyd, Clare F. McCoy, Marcella C. McBride, Karen-Leigh Edwards, Stephen Ampofo, R. Karl Malcolm. (2013) A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. European Journal of Pharmaceutical Sciences 48:3, 406-415
113
Beryl A. Koblin, Barbara Metch, Richard M. Novak, Cecilia Morgan, Debbie Lucy, Debora Dunbar, Parrie Graham, Edith Swann, Tamra Madenwald, Gina Escamilia, Ian Frank. (2013) Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials. JAIDS Journal of Acquired Immune Deficiency Syndromes1
114
Lung Vu, Sylvia Adebajo, Waimar Tun, Meredith Sheehy, Andrew Karlyn, Jean Njab, Aderemi Azeez, Babatunde Ahonsi. (2013) High HIV Prevalence among Men who Have Sex with Men in Nigeria. JAIDS Journal of Acquired Immune Deficiency Syndromes1
115
Sandra I. McCoy, Karen Shiu, Tyler E. Martz, Carla Dillard Smith, Loris Mattox, Dale Gluth, Neena Murgai, Marsha Martin, Nancy S. Padian. (2013) Improving the Efficiency of HIV Testing With Peer Recruitment, Financial Incentives, and the Involvement of Persons Living with HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes1
116
J. Y. Dai, P. B. Gilbert, J. P. Hughes, E. R. Brown. (2013) Estimating the Efficacy of Preexposure Prophylaxis for HIV Prevention Among Participants With a Threshold Level of Drug Concentration. American Journal of Epidemiology 177:3, 256-263
117
Amy L. Herrick, Ron Stall, Hilary Goldhammer, James E. Egan, Kenneth H. Mayer. (2013) Resilience as a Research Framework and as a Cornerstone of Prevention Research for Gay and Bisexual Men: Theory and Evidence. AIDS and Behavior
118
Ronald H. Gray, Maria J. Wawer. (2013) Infection in 2012: Mixed results of pre-exposure prophylaxis for HIV prevention. Nature Reviews Urology 10:2, 74-75
119
Jared Baeten, Connie Celum. (2013) Systemic and Topical Drugs for the Prevention of HIV Infection: Antiretroviral Pre-exposure Prophylaxis. Annual Review of Medicine 64:1, 219-232
120
H. In: Ferri's Clinical Advisor 2013. Elsevier, 2013:447-566.
121
Raph L. Hamers, Kim C.E. Sigaloff, Cissy Kityo, Peter Mugyenyi, Tobias F. Rinke de Wit. (2013) Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Current Opinion in HIV and AIDS 8:1, 19-26
122
Catherine A. Hankins, Mark R. Dybul. (2013) The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission. Current Opinion in HIV and AIDS 8:1, 50-58
123
Janet M. Blair, Lynn A. Paxton, Mary L. Kamb. HIV and AIDS in Women. In: Women and Health. Elsevier, 2013:505-522.
124
James W. Curran, Richard A. Crosby. (2013) Pre-Exposure Prophylaxis for HIV. American Journal of Preventive Medicine 44:1, S163-S166
125
Mitchell J. Warren, Emily S. Bass. (2013) From Efficacy to Impact. American Journal of Preventive Medicine 44:1, S167-S170
126
E. Jennifer Edelman, David A. Fiellin. (2013) Moving HIV Pre-Exposure Prophylaxis Into Clinical Settings. American Journal of Preventive Medicine 44:1, S86-S90
127
Dawn K. Smith, John Beltrami. (2013) A Proposed Framework to Monitor Daily Oral Antiretroviral Pre-Exposure Prophylaxis in the U.S. American Journal of Preventive Medicine 44:1, S141-S146
128
Sylvia Trent-Adams, Laura W. Cheever. (2013) Providing HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S147-S150
129
James W. Dearing, Dawn K. Smith, R. Sam Larson, Carole A. Estabrooks. (2013) Designing for Diffusion of a Biomedical Intervention. American Journal of Preventive Medicine 44:1, S70-S76
130
Mitchell H. Katz. (2013) Pre-Exposure Prophylaxis for HIV. American Journal of Preventive Medicine 44:1, S161-S162
131
James D. Campbell, Jeffrey H. Herbst, Robert T. Koppenhaver, Dawn K. Smith. (2013) Antiretroviral Prophylaxis for Sexual and Injection Drug Use Acquisition of HIV. American Journal of Preventive Medicine 44:1, S63-S69
132
Linda J. Koenig, Cynthia Lyles, Dawn K. Smith. (2013) Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S91-S98
133
Sean Philpott. (2013) Social Justice, Public Health Ethics, and the Use of HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S137-S140
134
Stephanie E. Cohen, Albert Y. Liu, Kyle T. Bernstein, Susan Philip. (2013) Preparing for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S80-S85
135
Mohan J. Dutta. (2013) Disseminating HIV Pre-Exposure Prophylaxis Information in Underserved Communities. American Journal of Preventive Medicine 44:1, S133-S136
136
Mark W. Thrun. (2013) Provider-Initiated HIV–Risk Behavior Counseling in the Context of HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S108-S111
137
Lindsay Culp, Lisa Caucci. (2013) State Adolescent Consent Laws and Implications for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S119-S124
138
C. Kevin Malotte. (2013) Brief Risk-Reduction Counseling in Clinical Settings for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine 44:1, S112-S118
139
Craig S. Pace, Marshall W. Fordyce, David Franco, Chia-Ying Kao, Michael S. Seaman, David D. Ho. (2013) Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:1, 1-9
140
Dobromir T. Dimitrov, Benoît R. Mâsse, Marie-Claude Boily. (2013) Beating the Placebo in HIV Prevention Efficacy Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:1, 95-101
141
Stefan Rowniak, Carmen Portillo. (2013) Pre-Exposure Prophylaxis: An Ethical Discussion. Journal of the Association of Nurses in AIDS Care 24:1, 6-10
142
Ide Cremin, Ramzi Alsallaq, Mark Dybul, Peter Piot, Geoffrey Garnett, Timothy B. Hallett. (2013) The new role of antiretrovirals in combination HIV prevention. AIDS 27:3, 447-458
143
Susie Hoffman. (2013) The Female Condom in the Age of Antiretroviral-Based HIV Prevention. Journal of Women's Health 22:1, 7-8
144
Rena Greifinger, Michelle Batchelor, Cynthia Fair. (2013) Improving Engagement and Retention in Adult Care Settings for Lesbian, Gay, Bisexual, Transgender and Questioning (LGBTQ) Youth Living with HIV: Recommendations for Health Care Providers. Journal of Gay & Lesbian Mental Health 17:1, 80-95
145
John A. Davis. (2013) HIV and the LGBT Community: A Medical Update. Journal of Gay & Lesbian Mental Health 17:1, 64-79
146
Timothy E. Morey, Matthew Booth, Scott Wasdo, Judith Wishin, Brian Quinn, Daniel Gonzalez, Hartmut Derendorf, Susan P. McGorray, Jane Simoni, Richard J. Melker, Donn M. Dennis. (2013) Oral Adherence Monitoring Using a Breath Test to Supplement Highly Active Antiretroviral Therapy. AIDS and Behavior 17:1, 298-306
147
Stephen J O'Brien, Sher L Hendrickson. (2013) Host genomic influences on HIV/AIDS. Genome Biology 14:1, 201
148
Nina Derby, Thomas Zydowsky, Melissa Robbiani. (2013) In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?. Expert Review of Anti-infective Therapy 11:1, 5-8
149
Quarraisha Abdool Karim, Cheryl Baxter. (2013) Microbicides for the prevention of sexually transmitted HIV infection. Expert Review of Anti-infective Therapy 11:1, 13-23
150
Kristine Torjesen, Jeanne M. Marrazzo, Sharon L. Hillier, Willard Cates. Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention. In: Sexually Transmitted Diseases. Elsevier, 2013:213-227.
151
C. William Wester, Sophie Limou, Cheryl A. Winkler. HIV Pharmacogenetics and Pharmacogenomics. In: Genomic and Personalized Medicine. Elsevier, 2013:1211-1229.
152
Vincenzo Puro, Antonio Palummieri, Gabriella De Carli, Pierluca Piselli, Giuseppe Ippolito. (2013) Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infectious Diseases 13:1, 217
153
Philip J Peters, Barbara J Marston, Paul J Weidle, John T Brooks. Human Immunodeficiency Virus Infection. In: Hunter's Tropical Medicine and Emerging Infectious Disease. Elsevier, 2013:217-247.
154
Adi Moseri, Subramanyam Tantry, Fa-Xiang Ding, Fred Naider, Jacob Anglister. (2012) Synergism Between a CD4-Mimic Peptide and Antibodies Elicited by a Constrained V3 Peptide. AIDS Research and Human Retroviruses121226065029006
155
Arunrat Tangmunkongvorakul, Suwat Chariyalertsak, K. Rivet Amico, Pongpun Saokhieo, Vorawan Wannalak, Thirayut Sangangamsakun, Pedro Goicochea, Robert Grant. (2012) Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care1-7
156
Fatou Maria Dramé, Sarah Peitzmeier, Magda Lopes, Marième Ndaw, Abdoulaye Sow, Daouda Diouf, Stefan Baral. (2012) Gay men and other men who have sex with men in West Africa: evidence from the field. Culture, Health & Sexuality1-15
157
Christine Bruno, Parya Saberi. (2012) Pharmacists as providers of HIV pre-exposure prophylaxis. International Journal of Clinical Pharmacy 34:6, 803-806
158
Patrick Lacor. (2012) Preparing for PrEP. The European Journal of Contraception and Reproductive Health Care 17:6, 482-486
159
Susanne Strömdahl, Abimbola Onigbanjo Williams, Bede Eziefule, Godwin Emmanuel, Stella Iwuagwu, Oliver Anene, Ifeanyi Orazulike, Chris Beyrer, Stefan Baral. (2012) Associations of Consistent Condom Use Among Men Who Have Sex with Men in Abuja, Nigeria. AIDS Research and Human Retroviruses 28:12, 1756-1762
160
Wiriya Rutvisuttinunt, Sunee Sirivichayakul, Sineenart Oota, Vatcharain Assawadarachai, Kultida Poltavee, Hathairat Savadsuk, Supanit Pattanachaiwit, Suwittra Chaemchuen, Miguel A. Arroyo, Robert M. Paris, Nelson L. Michael, Jerome H. Kim, Kiat Ruxrungtham, Mark de Souza, Praphan Phanuphak, Sodsai Tovanabutra. (2012) Two Unique Recombinant Forms Identified in Incident HIV Type 1 Infections in Thai Blood Donors. AIDS Research and Human Retroviruses 28:12, 1703-1711
161
Christina Psaros, Jennifer Barinas, Gregory K. Robbins, C. Andres Bedoya, Steven A. Safren, Elyse R. Park. (2012) Intimacy and Sexual Decision Making: Exploring the Perspective of HIV Positive Women Over 50. AIDS Patient Care and STDs 26:12, 755-760
162
Tamaryn L. Crankshaw, Lynn T. Matthews, Janet Giddy, Angela Kaida, Norma C. Ware, Jennifer A. Smit, David R. Bangsberg. (2012) A conceptual framework for understanding HIV risk behavior in the context of supporting fertility goals among HIV-serodiscordant couples. Reproductive Health Matters 20:39, 50-60
163
Felix M. Muchomba, Robin E. Gearing, Jane M. Simoni, Nabila El-Bassel. (2012) State of The Science of Adherence in Pre-Exposure Prophylaxis and Microbicide Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 61:4, 490-498
164
Edith Jasny, Suzanne Geer, Ines Frank, Panagiotis Vagenas, Meropi Aravantinou, Andres M. Salazar, Jeffrey D. Lifson, Michael Piatak, Agegnehu Gettie, James L. Blanchard, Melissa Robbiani. (2012) Characterization of Peripheral and Mucosal Immune Responses In Rhesus Macaques on Long-Term Tenofovir and Emtricitabine Combination Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 61:4, 425-435
165
KEVIN MICHAEL OʼHARA. (2012) Pre-exposure prophylaxis: Where HIV prevention and responsibility intersect. Journal of the American Academy of Physician Assistants 25:12, 61-62
166
Eric T. Roberts, Derrick D. Matthews. (2012) HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. Social Science & Medicine 75:9, 1555-1561
167
Alexander C. Tsai. (2012) A typology of structural approaches to HIV prevention: A commentary on Roberts and Matthews. Social Science & Medicine 75:9, 1562-1567
168
Stefan D. Baral, Susanne Strömdahl, Chris Beyrer. (2012) The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Current Opinion in HIV and AIDS 7:6, 563-568
169
I. Mary Poynten, Iryna Zablotska, Andrew E. Grulich. (2012) Considerations regarding antiretroviral chemoprophylaxis in MSM. Current Opinion in HIV and AIDS 7:6, 549-556
170
Lynn A. Paxton. (2012) Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings. Current Opinion in HIV and AIDS 7:6, 557-562
171
Bisrat K. Abraham, Roy Gulick. (2012) Next-generation oral preexposure prophylaxis. Current Opinion in HIV and AIDS 7:6, 600-606
172
Lynn T. Matthews, Jennifer A. Smit, Susan Cu-Uvin, Deborah Cohan. (2012) Antiretrovirals and safer conception for HIV-serodiscordant couples. Current Opinion in HIV and AIDS 7:6, 569-578
173
Ian McGowan. (2012) Rectal microbicide development. Current Opinion in HIV and AIDS 7:6, 526-533
174
Bruce R. Schackman, Ashley A. Eggman. (2012) Cost–effectiveness of pre-exposure prophylaxis for HIV. Current Opinion in HIV and AIDS 7:6, 587-592
175
Douglas Krakower, Kenneth H. Mayer. (2012) Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Current Opinion in HIV and AIDS 7:6, 593-599
176
J. Gerardo García-Lerma, Walid Heneine. (2012) Animal models of antiretroviral prophylaxis for HIV prevention. Current Opinion in HIV and AIDS 7:6, 505-513
177
Jared Baeten, Connie Celum. (2012) Oral antiretroviral chemoprophylaxis. Current Opinion in HIV and AIDS 7:6, 514-519
178
Simi Gunaseelan, Philippe A. Gallay, Michael D. Bobardt, Charlene S. Dezzutti, Timothy Esch, Richard Maskiewicz. (2012) Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices. Pharmaceutical Research 29:11, 3156-3168
179
Randall Tressler, Catherine Godfrey. (2012) NRTI Backbone in HIV Treatment. Drugs 72:16, 2051-2062
180
Justin J. O’Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Reply to ‘Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial’. AIDS 26:17, 2262-2263
181
Peter A. Anton, Ross D. Cranston, Angela Kashuba, Craig W. Hendrix, Namandjé N. Bumpus, Nicola Richardson-Harman, Julie Elliott, Laura Janocko, Elena Khanukhova, Robert Dennis, William G. Cumberland, Chuan Ju, Alex Carballo-Diéguez, Christine Mauck, Ian McGowan. (2012) RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses 28:11, 1412-1421
182
Hela Saidi, Mohammad-Ali Jenabian, Laurent Belec. (2012) Understanding Factors That Modulate HIV Infection at the Female Genital Tract Mucosae for the Rationale Design of Microbicides. AIDS Research and Human Retroviruses 28:11, 1485-1497
183
Meropi Aravantinou, Rachel Singer, Nina Derby, Giulia Calenda, Paul Mawson, Ciby J. Abraham, Radhika Menon, Samantha Seidor, Daniel Goldman, Jessica Kenney, Guillermo Villegas, Agegnehu Gettie, James Blanchard, Jeffrey D. Lifson, Michael Piatak, José A. Fernández-Romero, Thomas M. Zydowsky, Natalia Teleshova, Melissa Robbiani. (2012) The Nonnucleoside Reverse Transcription Inhibitor MIV-160 Delivered from an Intravaginal Ring, But Not from a Carrageenan Gel, Protects Against Simian/Human Immunodeficiency Virus-RT Infection. AIDS Research and Human Retroviruses 28:11, 1467-1475
184
Charlene S. Dezzutti, Cory Shetler, Alamelu Mahalingam, Shweta R. Ugaonkar, Garry Gwozdz, Karen W. Buckheit, Robert W. Buckheit. (2012) Safety and efficacy of tenofovir/IQP-0528 combination gels – A dual compartment microbicide for HIV-1 prevention. Antiviral Research 96:2, 221-225
185
G. Pialoux, J. Chas, P. Bonnard. (2012) PreP un nouvel outil de prévention contre le VIH. Journal des Anti-infectieux 14:4, 175-179
186
Mandana Mehta, Fred Semitala, Lutgarde Lynen, Robert Colebunders. (2012) Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?. Expert Review of Anti-infective Therapy 10:11, 1287-1296
187
Jose R. Castillo-Mancilla, Jia-Hua Zheng, Joseph E. Rower, Amie Meditz, Edward M. Gardner, Julie Predhomme, Caitlin Fernandez, Jacob Langness, Jennifer J. Kiser, Lane R. Bushman, Peter L. Anderson. (2012) Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. AIDS Research and Human Retroviruses121010062750004
188
Mark I. Ryder, Wipawee Nittayananta, Maeve Coogan, Deborah Greenspan, John S. Greenspan. (2012) Periodontal disease in HIV/AIDS. Periodontology 2000 60:1, 78-97
189
Peter A. Newman, Sung-Jae Lee, Surachet Roungprakhon, Suchon Tepjan. (2012) Demographic and Behavioral Correlates of HIV Risk among Men and Transgender Women Recruited from Gay Entertainment Venues and Community-based Organizations in Thailand: Implications for HIV Prevention. Prevention Science 13:5, 483-492
190
Ranajit Pal, Lindsey Galmin, Lara E. Pereira, Bin Li, Jining Zhang, Daniel Li, Jesse Francis, Janet M. McNicholl, Deborah E. Weiss, James M. Smith. (2012) Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. Virology 432:1, 173-183
191
Peter A. Newman, Surachet Roungprakhon, Suchon Tepjan, Suzy Yim, Rachael Walisser. (2012) A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Global Public Health 7:9, 1009-1024
192
John Schneider, Rupali Kumar, Rakhi Dandona, Prem Kumar, Anil Kumar, Vemu Lakshmi, Edward Laumann, Kenneth Mayer, Lalit Dandona. (2012) Social Network and Risk-Taking Behavior Most Associated with Rapid HIV Testing, Circumcision, and Preexposure Prophylaxis Acceptability Among High-Risk Indian Men. AIDS Patient Care and STDs 26:10, 631-640
193
Erik De Clercq. (2012) Human viral diseases: what is next for antiviral drug discovery?. Current Opinion in Virology 2:5, 572-579
194
Zabrina L Brumme, Denis R Chopera, Mark A Brockman. (2012) Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. Current Opinion in Virology 2:5, 599-605
195
Stephen Frausto, Emily Lee, Hengli Tang. (2012) Targeting host cofactors to inhibit viral infection. Frontiers in Biology 7:5, 445-458
196
Jason W. Mitchell, Luis Garcia, Donna Champeau, S. Marie Harvey, Andrew E. Petroll. (2012) HIV-Negative Seroconcordant Gay Male Couples' Attitudes, Intentions, and Perceived Behavioral Control for Planned Condom Use Within and Outside of Their Relationships. International Journal of Sexual Health 24:4, 239-253
197
Dawn K. Smith, Lauren Toledo, Donna Jo Smith, Mary Anne Adams, Richard Rothenberg. (2012) Attitudes and Program Preferences of African-American Urban Young Adults About Pre-Exposure Prophylaxis (PrEP). AIDS Education and Prevention 24:5, 408-421
198
Michael P. Carey, Lori A. J. Scott-Sheldon, Peter A. Vanable. HIV/AIDS. In: Handbook of Psychology, Second Edition. John Wiley & Sons, Inc., 2012.
199
Lisa A. Eaton, Tania B. Huedo-Medina, Seth C. Kalichman, Jennifer A. Pellowski, Michael J. Sagherian, Michelle Warren, Blair T. Johnson, Ami R. Popat. (2012) Meta-Analysis of Single-Session Behavioral Interventions to Prevent Sexually Transmitted Infections: Implications for Bundling Prevention Packages. American Journal of Public Healthe1-e11
200
Derrick Louz, Hans E. Bergmans, Birgit P. Loos, Rob C. Hoeben. (2012) Animal models in virus research: their utility and limitations. Critical Reviews in Microbiology1-37
201
Mitzy Gafos, Misiwe A. Mzimela, Hlengiwe B. Ndlovu, Sheena McCormack, Nuala McGrath. (2012) How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community. AIDS Care1-6
202
P. L. Anderson, D. V. Glidden, A. Liu, S. Buchbinder, J. R. Lama, J. V. Guanira, V. McMahan, L. R. Bushman, M. Casapia, O. Montoya-Herrera, V. G. Veloso, K. H. Mayer, S. Chariyalertsak, M. Schechter, L.-G. Bekker, E. G. Kallas, R. M. Grant, . (2012) Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Science Translational Medicine 4:151, 151ra125-151ra125
203
Virginia A Fonner, Julie Denison, Caitlin E Kennedy, Kevin O'Reilly, Michael Sweat, Virginia A Fonner. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
204
Cindy Patton, Hye Jin Kim. (2012) The Cost of Science. Journal of Bioethical Inquiry 9:3, 295-310
205
Perry N. Halkitis. (2012) Obama, Marriage Equality, and the Health of Gay Men. American Journal of Public Health 102:9, 1628-1629
206
E. N. Kersh, W. Luo, Q. Zheng, D. R. Adams, D. Hanson, A. S. Youngpairoj, M.-e. Cong, K. Butler, R. M. Hendry, J. M. McNicholl, W. Heneine, J. G. Garcia-Lerma. (2012) Reduced Inflammation and CD4 Loss in Acute SHIV Infection During Oral Pre-Exposure Prophylaxis. Journal of Infectious Diseases 206:5, 770-779
207
Jennifer Koen, Zaynab Essack, Catherine Slack, Graham Lindegger, Peter A. Newman. (2012) ‘It Looks Like You Just Want Them When Things Get Rough’: Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in HIV Prevention Trials. Developing World Bioethicsn/a-n/a
208
Nicholas Muraguri, Marleen Temmerman, Scott Geibel. (2012) A decade of research involving men who have sex with men in sub-Saharan Africa: Current knowledge and future directions. SAHARA-J: Journal of Social Aspects of HIV/AIDS 9:3, 137-147
209
K. Rebe, P. Semugoma, J. A. McIntyre. (2012) New HIV prevention technologies and their relevance to MARPS in African epidemics. SAHARA-J: Journal of Social Aspects of HIV/AIDS 9:3, 164-166
210
Havlir , Diane , Beyrer , Chris , . (2012) The Beginning of the End of AIDS?. New England Journal of Medicine 367:8, 685-687
Free Full Text211
Alex Carballo-Diéguez, Timothy Frasca, Ivan Balan, Mobolaji Ibitoye, Curtis Dolezal. (2012) Use of a Rapid HIV Home Test Prevents HIV Exposure in a High Risk Sample of Men Who Have Sex With Men. AIDS and Behavior
212
Hela Saidi, Mohammad-Ali Jenabian, LAURENT BELEC. (2012) Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides. AIDS Research and Human Retroviruses120807025326009
213
Van Damme , Lut , Corneli , Amy , Ahmed , Khatija , Agot , Kawango , Lombaard , Johan , Kapiga , Saidi , Malahleha , Mookho , Owino , Fredrick , Manongi , Rachel , Onyango , Jacob , Temu , Lucky , Monedi , Modie Constance , Mak'Oketch , Paul , Makanda , Mankalimeng , Reblin , Ilse , Makatu , Shumani Elsie , Saylor , Lisa , Kiernan , Haddie , Kirkendale , Stella , Wong , Christina , Grant , Robert , Kashuba , Angela , Nanda , Kavita , Mandala , Justin , Fransen , Katrien , Deese , Jennifer , Crucitti , Tania , Mastro , Timothy D. , Taylor , Douglas , . (2012) Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine 367:5, 411-422
Free Full Text214
Cohen , Myron S. , Baden , Lindsey R. , . (2012) Preexposure Prophylaxis for HIV — Where Do We Go from Here?. New England Journal of Medicine 367:5, 459-461
Free Full Text215
Baeten , Jared M. , Donnell , Deborah , Ndase , Patrick , Mugo , Nelly R. , Campbell , James D. , Wangisi , Jonathan , Tappero , Jordan W. , Bukusi , Elizabeth A. , Cohen , Craig R. , Katabira , Elly , Ronald , Allan , Tumwesigye , Elioda , Were , Edwin , Fife , Kenneth H. , Kiarie , James , Farquhar , Carey , John-Stewart , Grace , Kakia , Aloysious , Odoyo , Josephine , Mucunguzi , Akasiima , Nakku-Joloba , Edith , Twesigye , Rogers , Ngure , Kenneth , Apaka , Cosmas , Tamooh , Harrison , Gabona , Fridah , Mujugira , Andrew , Panteleeff , Dana , Thomas , Katherine K. , Kidoguchi , Lara , Krows , Meighan , Revall , Jennifer , Morrison , Susan , Haugen , Harald , Emmanuel-Ogier , Mira , Ondrejcek , Lisa , Coombs , Robert W. , Frenkel , Lisa , Hendrix , Craig , Bumpus , Namandjé N. , Bangsberg , David , Haberer , Jessica E. , Stevens , Wendy S. , Lingappa , Jairam R. , Celum , Connie , . (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine 367:5, 399-410
Free Full Text216
Thigpen , Michael C. , Kebaabetswe , Poloko M. , Paxton , Lynn A. , Smith , Dawn K. , Rose , Charles E. , Segolodi , Tebogo M. , Henderson , Faith L. , Pathak , Sonal R. , Soud , Fatma A. , Chillag , Kata L. , Mutanhaurwa , Rodreck , Chirwa , Lovemore Ian , Kasonde , Michael , Abebe , Daniel , Buliva , Evans , Gvetadze , Roman J. , Johnson , Sandra , Sukalac , Thom Thomas , Vasavi T. , Hart , Clyde , Johnson , Jeffrey A. , Malotte , C. Kevin , Hendrix , Craig W. , Brooks , John T. , . (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine 367:5, 423-434
Free Full Text217
(2012) Preexposure Prophylaxis for HIV Prevention. New England Journal of Medicine 367:5, 462-465
Free Full Text218
John T. Brooks, Kate Buchacz, Kelly A. Gebo, Jonathan Mermin. (2012) HIV Infection and Older Americans: The Public Health Perspective. American Journal of Public Health 102:8, 1516-1526
219
Guido Antonelli, Ombretta Turriziani. (2012) Antiviral therapy: old and current issues. International Journal of Antimicrobial Agents 40:2, 95-102
220
Vagish Hemmige, Rachel McFadden, Scott Cook, Hui Tang, John A. Schneider. (2012) HIV Prevention Interventions to Reduce Racial Disparities in the United States: A Systematic Review. Journal of General Internal Medicine 27:8, 1047-1067
221
L. Chonco, M. Pion, E. Vacas, B. Rasines, M. Maly, M.J. Serramía, L. López-Fernández, J. De la Mata, S. Alvarez, R. Gómez, M.A. Muñoz-Fernández. (2012) Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. Journal of Controlled Release 161:3, 949-958
222
Christophe Vanpouille, Anush Arakelyan, Leonid Margolis. (2012) Microbicides: still a long road to success. Trends in Microbiology 20:8, 369-375
223
Lisa M. McDaid, Graham J. Hart. (2012) Willingness to Participate in Future HIV Prevention Studies Among Gay and Bisexual Men in Scotland, UK: A Challenge for Intervention Trials. AIDS and Behavior 16:6, 1420-1429
224
Myron S. Cohen, Kathryn E. Muessig, M. Kumi Smith, Kimberly A. Powers, Angela D.M. Kashuba. (2012) Antiviral agents and HIV prevention. AIDS 26:13, 1585-1598
225
Janni J. Kinsler, William E. Cunningham, César R. Nureña, Carsten Nadjat-Haiem, Beatriz Grinsztejn, Martin Casapia, Orlando Montoya-Herrera, Jorge Sánchez, Jerome T. Galea. (2012) Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities. AIDS and Behavior 16:6, 1436-1447
226
Sandhya Vasan, Nelson L Michael. (2012) Improved outlook on HIV-1 prevention and vaccine development. Expert Opinion on Biological Therapy 12:8, 983-994
227
Alex Sigal, David Baltimore. (2012) As Good As It Gets? The Problem of HIV Persistence despite Antiretroviral Drugs. Cell Host & Microbe 12:2, 132-138
228
Yelina Alvarez, Michael Tuen, Arthur Nàdas, Catarina E. Hioe. (2012) In Vitro Restoration of Th17 Response During HIV Infection with an Antiretroviral Drug and Th17 Differentiation Cytokines. AIDS Research and Human Retroviruses 28:8, 823-834
229
Caroline A. Ryan, Shanti R. Conly, David L. Stanton, Nina S. Hasen. (2012) Prevention of Sexually Transmitted HIV Infections Through the Presidentʼs Emergency Plan for AIDS Relief. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S70-S77
230
Nancy S. Padian, Michael T. Isbell, Elizabeth S. Russell, M. Essex. (2012) The Future of HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S22-S26
231
Benjamin H. Chi, Michelle R. Adler, Omotayo Bolu, Dorothy Mbori-Ngacha, Didier K. Ekouevi, Anna Gieselman, Tsungai Chipato, Chewe Luo, B. Ryan Phelps, Craig McClure, Lynne M. Mofenson, Jeffrey S. A. Stringer. (2012) Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US Presidentʼs Emergency Plan for AIDS Relief. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S78-S87
232
Beryl A. Koblin, Kenneth H. Mayer, Elizabeth Noonan, Ching-Yun Wang, Michael Marmor, Jorge Sanchez, Stephen J. Brown, Michael N. Robertson, Susan P. Buchbinder. (2012) Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 60:4, 405-413
233
Richard Needle, Joe Fu, Chris Beyrer, Virginia Loo, Abu S. Abdul-Quader, James A. McIntyre, Zhijun Li, Jessie K. K. Mbwambo, Mercy Muthui, Billy Pick. (2012) PEPFARʼs Evolving HIV Prevention Approaches for Key Populations—People Who Inject Drugs, Men Who Have Sex With Men, and Sex Workers. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S145-S151
234
Dawn K. Smith, Sherri L. Pals, Jeffrey H. Herbst, Sanjyot Shinde, James W. Carey. (2012) Development of a Clinical Screening Index Predictive of Incident HIV Infection Among Men Who Have Sex With Men in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 60:4, 421-427
235
M. Juliana McElrath, Bruce D. Walker. (2012) Is an HIV Vaccine Possible?. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S41-S43
236
Eric Goosby, Mark Dybul, Anthony A. Fauci, Joe Fu, Thomas Walsh, Richard Needle, Paul Bouey. (2012) The United States Presidentʼs Emergency Plan for AIDS Relief. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S51-S56
237
Meropi Aravantinou, Rachel Singer, Nina Derby, Giulia Calenda, Paul Mawson, Ciby Abraham, Radhika Menon, Samantha Seidor, Daniel Goldman, Jessica Kenney, Guillermo Villegas, Agegnehu Gettie, James Blanchard, Jeffrey Lifson, Michael Piatak, Jose A Fernandez-Romero, Thomas Zydowsky, Natalia Teleshova, Melissa Robbiani. (2012) The NNRTI MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against SHIV-RT infection. AIDS Research and Human Retroviruses120720191104008
238
Michael S. MacVeigh, Maria K. Kosmetatos, James E. McDonald, Joan L. Reeder, Debby A. Parrish, Thomas P. Young. (2012) Prevalence of Drug-Resistant HIV Type 1 at the Time of Initiation of Antiretroviral Therapy in Portland, Oregon. AIDS Research and Human Retroviruses120718112500009
239
U. M. Parikh, J. W. Mellors. (2012) HIV-1 Drug Resistance Resulting from Antiretroviral Therapy Far Exceeds That From Pre-exposure Prophylaxis. Clinical Infectious Diseases 55:2, 303-304
240
C. B. Hurt, J. J. Eron, M. S. Cohen. (2012) Reply to Parikh and Mellors. Clinical Infectious Diseases 55:2, 304-304
241
Elizabeth T. Montgomery, A. Straten, H. Cheng, L. Wegner, G. Masenga, C. Mollendorf, L. Bekker, S. Ganesh, K. Young, J. Romano, A. Nel, C. Woodsong. (2012) Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use. AIDS and Behavior
242
Charles I Okwundu, Olalekan A Uthman, Christy AN Okoromah, Charles I Okwundu. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
243
Audrey Pettifor, Catherine MacPhail, Nadia Nguyen, Molly Rosenberg. (2012) Can Money Prevent the Spread of HIV? A Review of Cash Payments for HIV Prevention. AIDS and Behavior
244
Alex Carballo-Diéguez, Timothy Frasca, Curtis Dolezal, Ivan Balan. (2012) Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. Journal of Sex Research 49:4, 379-387
245
Gift Trapence, Chris Collins, Sam Avrett, Robert Carr, Hugo Sanchez, George Ayala, Daouda Diouf, Chris Beyrer, Stefan D Baral. (2012) From personal survival to public health: community leadership by men who have sex with men in the response to HIV. The Lancet 380:9839, 400-410
246
Erik De Clercq. (2012) Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?. Medicinal Research Reviews 32:4, 765-785
247
Patrick S Sullivan, Alex Carballo-Diéguez, Thomas Coates, Steven M Goodreau, Ian McGowan, Eduard J Sanders, Adrian Smith, Prabuddhagopal Goswami, Jorge Sanchez. (2012) Successes and challenges of HIV prevention in men who have sex with men. The Lancet 380:9839, 388-399
248
William A. Fisher. (2012) “I Think Having the Option Available is a No-Brainer”: Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. Journal of Sex Research 49:4, 388-389
249
Wendy A. Burgers, Amapola Manrique, David Masopust, Lyle R. McKinnon, Matthew R. Reynolds, Morgane Rolland, Catherine Blish, Gerald K. Chege, Rhonda Curran, William Fischer, Carolina Herrera, D. Noah Sather. (2012) Measurements of Immune Responses for Establishing Correlates of Vaccine Protection Against HIV. AIDS Research and Human Retroviruses 28:7, 641-648
250
Chris Beyrer, Patrick S Sullivan, Jorge Sanchez, David Dowdy, Dennis Altman, Gift Trapence, Chris Collins, Elly Katabira, Michel Kazatchkine, Michel Sidibe, Kenneth H Mayer. (2012) A call to action for comprehensive HIV services for men who have sex with men. The Lancet 380:9839, 424-438
251
Alain Giami, Christophe Perrey. (2012) Transformations in the Medicalization of Sex: HIV Prevention between Discipline and Biopolitics. Journal of Sex Research 49:4, 353-361
252
Sorachai Nitayaphan, Viseth Ngauy, Robert O’Connell, Jean-Louis Excler. (2012) HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Review of Vaccines 11:7, 805-819
253
Jaclyn M. White, Matthew J. Mimiaga, Douglas S. Krakower, Kenneth H. Mayer. (2012) Evolution of Massachusetts Physician Attitudes, Knowledge, and Experience Regarding the Use of Antiretrovirals for HIV Prevention. AIDS Patient Care and STDs120613073450003
254
Kevin O. Saunders, Rebecca S. Rudicell, Gary J. Nabel. (2012) The design and evaluation of HIV-1 vaccines. AIDS 26:10, 1293-1302
255
Róbert Sendula, Erika Orbán, Ferenc Hudecz, Gyula Sági, István Jablonkai. (2012) Synthesis and Cytotoxic Activity of Novel 5-Substituted-1-(β-L-Arabinofuranosyl) Pyrimidine Nucleosides. Nucleosides, Nucleotides and Nucleic Acids 31:6, 482-500
256
Salim S Abdool Karim, Quarraisha Abdool Karim. (2012) Antiretroviral prophylaxis for HIV prevention reaches a key milestone. The Lancet 379:9831, 2047-2048
257
Paul W. Denton, J. Victor Garcia. (2012) Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends in Microbiology 20:6, 268-274
258
Louise Kuhn, Marc Bulterys. (2012) Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?. AIDS 26:9, 1167-1169
259
Marie Laga, Peter Piot. (2012) Prevention of sexual transmission of HIV. AIDS 26:10, 1223-1229
260
Angela DM Kashuba, Kristine B Patterson, Julie B Dumond, Myron S Cohen. (2012) Pre-exposure prophylaxis for HIV prevention: how to predict success. The Lancet 379:9835, 2409-2411
261
Virginie Supervie, Sally Blower. (2012) Predicting effect of pre-exposure prophylaxis on HIV epidemics. The Lancet 379:9835, 2423
262
(2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, e1-e89
263
Hong Shang, Junjie Xu, Xiaoxu Han, Jessica Spero Li, Kelly C. Arledge, Linqi Zhang. (2012) HIV prevention: Bring safe sex to China. Nature 485:7400, 576-577
264
D. H. Barouch, P. J. Klasse, J. Dufour, R. S. Veazey, J. P. Moore. (2012) Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences 109:22, 8694-8698
265
A. Straten, E. T. Montgomery, H. Cheng, L. Wegner, G. Masenga, C. Mollendorf, L. Bekker, S. Ganesh, K. Young, J. Romano, A. Nel, C. Woodsong. (2012) High Acceptability of a Vaginal Ring Intended as a Microbicide Delivery Method for HIV Prevention in African Women. AIDS and Behavior
266
Quarraisha Abdool Karim, Ayesha B. M. Kharsany, Janet A. Frohlich, Lise Werner, Mukelisiwe Mlotshwa, Bernadette T. Madlala, Salim S. Abdool Karim. (2012) HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. AIDS and Behavior
267
S. E. Reid, S. M. Topp, E. R. Turnbull, S. Hatwiinda, J. B. Harris, K. R. Maggard, S. T. Roberts, A. Kruuner, J. C. Morse, N. Kapata, C. Chisela, G. Henostroza. (2012) Tuberculosis and HIV Control in Sub-Saharan African Prisons: "Thinking Outside the Prison Cell". Journal of Infectious Diseases 205:suppl 2, S265-S273
268
R. P. Walensky, J.-E. Park, R. Wood, K. A. Freedberg, C. A. Scott, L.-G. Bekker, E. Losina, K. H. Mayer, G. R. Seage, A. D. Paltiel. (2012) The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. Clinical Infectious Diseases 54:10, 1504-1513
269
K. Mulligan, D. R. Harris, P. Emmanuel, R. A. Fielding, C. Worrell, B. G. Kapogiannis, D. Monte, J. Sleasman, C. M. Wilson, G. M. Aldrovandi, . (2012) Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network (ATN) Study 021B. Clinical Infectious Diseases
270
D Dolling, AN Phillips, V Delpech, D Pillay, PA Cane, AM Crook, J Shepherd, E Fearnhill, T Hill, D Dunn, . (2012) Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Medicine 13:5, 309-314
271
Erik De Clercq. (2012) Ten Paths to the Discovery of Antivirally Active Nucleoside and Nucleotide Analogues. Nucleosides, Nucleotides and Nucleic Acids 31:4, 339-352
272
Avnish Tripathi, Chinelo Ogbuanu, Mauda Monger, James J. Gibson, Wayne A. Duffus. (2012) Preexposure Prophylaxis for HIV Infection. Southern Medical Journal 105:4, 199-206
273
Fatih M Uckun, Pedro Cahn, Sanjive Qazi, Osmond D'Cruz. (2012) Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opinion on Investigational Drugs 21:4, 489-500
274
Amanda Clarke, Denise Hsu, Stephen J Kerr, Reshmie Ramautarsing, Pirapon June Ohata, Nadia Kancheva Landolt, Anchalee Avihingsanon, Wirach Maek-a-nantawat, Thanyawee Puthanakit, Torsak Bunupuradah, Wasana Prasitsuebsai, Jintanat Ananworanich, Praphan Phanuphak, Kiat Ruxrungtham. (2012) The 15th Bangkok International Symposium on HIV Medicine. Future Virology 7:4, 341-344
275
Jeffrey H. Herbst, Marlene Glassman, James W. Carey, Thomas M. Painter, Deborah J. Gelaude, Amy M. Fasula, Jerris L. Raiford, Arin E. Freeman, Camilla Harshbarger, Abigail H. Viall, David W. Purcell. (2012) Operational Research to Improve HIV Prevention in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:5, 530-536
276
Kenneth H. Mayer, Matthew J. Mimiaga, Marcy Gelman, Chris Grasso. (2012) Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:4, 354-359
277
Norma C. Ware, Monique A. Wyatt, Jessica E. Haberer, Jared M. Baeten, Alexander Kintu, Christina Psaros, Steven Safren, Elioda Tumwesigye, Connie L. Celum, David R. Bangsberg. (2012) Whatʼs Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:5, 463-468
278
Kathryn Curran, Jared M. Baeten, Thomas J. Coates, Ann Kurth, Nelly R. Mugo, Connie Celum. (2012) HIV-1 Prevention for HIV-1 Serodiscordant Couples. Current HIV/AIDS Reports
279
Thana Khawcharoenporn, Sabrina Kendrick, Kimberly Smith. (2012) HIV Risk Perception and Preexposure Prophylaxis Interest Among a Heterosexual Population Visiting a Sexually Transmitted Infection Clinic. AIDS Patient Care and STDs120309093020005
280
Tanuja N Gengiah, Cheryl Baxter, Leila E Mansoor, Ayesha BM Kharsany, Salim. S Abdool Karim. (2012) A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opinion on Investigational Drugs1-21
281
Salim S. Abdool Karim, Cheryl Baxter. (2012) Overview of microbicides for the prevention of human immunodeficiency virus. Best Practice & Research Clinical Obstetrics & Gynaecology
282
James Y. Dai, Peter B. Gilbert, Benoît R. Mâsse. (2012) Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials. Journal of the American Statistical Association 107:497, 52-65
283
Erik De Clercq. (2012) Pre-exposure chemoprophylaxis of HIV infection: Quo vadis?. Biochemical Pharmacology 83:5, 567-573
284
S.M. Owen. (2012) Testing for acute HIV infection. Current Opinion in HIV and AIDS 7:2, 125-130
285
Xuefeng Li, Hongyan Lu, Xiaoyan Ma, Yanming Sun, Xiong He, Chunmei Li, H. F. Raymond, Willi McFarland, Stephen W. Pan, Yiming Shao, Sten H. Vermund, Yan Xiao, Yuhua Ruan, Yujiang Jia. (2012) HIV/AIDS-Related Stigmatizing and Discriminatory Attitudes and Recent HIV Testing Among Men Who Have Sex With Men in Beijing. AIDS and Behavior
286
Charlene Flash, Douglas Krakower, Kenneth H. Mayer. (2012) The Promise of Antiretrovirals for HIV Prevention. Current Infectious Disease Reports
287
Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate, Sheela V. Godbole. (2012) Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences
288
Jane Anderson. (2012) Women and HIV. Current Opinion in Infectious Diseases 25:1, 58-65
289
Bruce L. Gilliam, Devang Patel, Rohit Talwani, Zelalem Temesgen. (2012) HIV in Africa: Challenges and Directions for the Next Decade. Current Infectious Disease Reports 14:1, 91-101
290
Connie Celum, Jared M. Baeten. (2012) Tenofovir-based pre-exposure prophylaxis for HIV prevention. Current Opinion in Infectious Diseases 25:1, 51-57
291
Valerie E. Stone. (2012) HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S.. Current Infectious Disease Reports 14:1, 53-60
292
Ariane van der Straten, Lut van Damme, Jessica E. Haberer, David R. Bangsberg. (2012) How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS1
293
Emilie Venables, Jonathan Stadler. (2012) ‘The study has taught me to be supportive of her’: empowering women and involving men in microbicide research. Culture, Health & Sexuality 14:2, 181-194
294
Matthew A. Price, Wasima Rida, Mary Mwangome, Gaudensia Mutua, Keren Middelkoop, Surita Roux, Haile S. Okuku, Linda-Gail Bekker, Omu Anzala, Elizabeth Ngugi, Gwynn Stevens, Paramesh Chetty, Pauli N. Amornkul, Eduard J. Sanders. (2012) Identifying At-Risk Populations in Kenya and South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:2, 185-193
295
Kenneth H. Mayer, Robert Ducharme, Nickolas D. Zaller, Philip A. Chan, Patricia Case, David Abbott, Irma I. Rodriguez, Timothy Cavanaugh. (2012) Unprotected Sex, Underestimated Risk, Undiagnosed HIV and Sexually Transmitted Diseases Among Men Who Have Sex With Men Accessing Testing Services in a New England Bathhouse. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:2, 194-198
296
Charles I Okwundu, Christy AN Okoromah, Prakeshkumar S Shah, Charles I Okwundu. Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
297
Nelson L. Michael. (2012) Rare serotype adenoviral vectors for HIV vaccine development. Journal of Clinical Investigation 122:1, 25-27
298
L. Mandelbrot. (2012) Désir d’enfant et VIH : le préservatif est-il dépassé ?. Gynécologie Obstétrique & Fertilité 40:1, 58-61
299
L. T. Matthews, T. Crankshaw, J. Giddy, A. Kaida, C. Psaros, N. C. Ware, J. A. Smit, D. R. Bangsberg. (2012) Reproductive Counseling by Clinic Healthcare Workers in Durban, South Africa: Perspectives from HIV-Infected Men and Women Reporting Serodiscordant Partners. Infectious Diseases in Obstetrics & Gynecology 2012, 1-9
300
Eric T. Roberts, Derrick D. Matthews. (2012) HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. Social Science & Medicine
301
Deborah Cohan, Shannon Weber, Ronald Goldschmidt. (2012) Safer conception options for HIV-serodiscordant couples. American Journal of Obstetrics and Gynecology 206:1, e21
302
Thomas J. Ketas, Sophie Holuigue, Katie Matthews, John P. Moore, Per Johan Klasse. (2012) Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology 422:1, 22-36
303
Shahin Lockman, Paul Sax. (2012) Treatment-for-prevention. Current Opinion in HIV and AIDS1
304
Anneke C. Grobler, Salim S. Abdool Karim. (2012) Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies. AIDS1
305
Koen K.A. Van Rompay. (2012) The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. AIDS Research and Human Retroviruses 28:1, 16-35
306
Justin J. O’Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Apparent declining efficacy in randomized trials. AIDS 26:2, 123-126
307
Marc M. Baum, Irina Butkyavichene, Joshua Gilman, Sean Kennedy, Etana Kopin, Amanda M. Malone, Cali Nguyen, Thomas J. Smith, David R. Friend, Meredith R. Clark, John A. Moss. (2012) An intravaginal ring for the simultaneous delivery of multiple drugs. Journal of Pharmaceutical Sciencesn/a-n/a
308
Richard A. Crosby, Willard Cates. (2012) Condom use: still a sexual health staple. Sexual Health 9:1, 1
309
Susanne Strömdahl, Abimbola Onigbanjo Williams, Bede Eziefule, Godwin Emmanuel, Stella Iwuagwu, Oliver Anene, Ifeanyi Orazulike, Chris Beyrer, Stefan Baral. (2012) Associations of Consistent Condom Use Among Men Who Have Sex with Men in Abuja, Nigeria. AIDS Research and Human Retroviruses120625113303009
310
J.A. Stockman. (2012) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. Yearbook of Pediatrics 2012, 271-272
311
Thomas R. Moench, Deirdre E. OʼHanlon, Richard A. Cone. (2012) Evaluation of Microbicide Gel Adherence Monitoring Methods. Sexually Transmitted Diseases1
312
Angela Kelly, Martha Kupul, Lisa Fitzgerald, Herick Aeno, James Neo, Richard Naketrumb, Peter Siba, John M Kaldor, Andrew Vallely. (2012) "Now we are in a different time; various bad diseases have come." Understanding men's acceptability of male circumcision for HIV prevention in a moderate prevalence setting.. BMC Public Health 12:1, 67
313
Renee Heffron, Deborah Donnell, Helen Rees, Connie Celum, Nelly Mugo, Edwin Were, Guy de Bruyn, Edith Nakku-Joloba, Kenneth Ngure, James Kiarie, Robert W Coombs, Jared M Baeten. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. The Lancet Infectious Diseases 12:1, 19-26
314
Ayesha Mirza, Mobeen H. Rathore. (2012) Pediatric HIV Infection. Advances in Pediatrics 59:1, 9-26
315
Mark W Hull, Julio SG Montaner. (2012) Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime time?. Clinical Investigation 2:1, 1-4
316
G. Bocharov, V. Chereshnev, I. Gainova, S. Bazhan, B. Bachmetyev, J. Argilaguet, J. Martinez, A. Meyerhans. (2012) Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. Mathematical Modelling of Natural Phenomena 7:5, 78-104
317
Qi Zheng, Susan Ruone, William M Switzer, Walid Heneine, J García-Lerma. (2012) Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. Retrovirology 9:1, 40
318
Susa Coffey, Paul A. Volberding. Overview of antiretroviral therapy. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:133-153.
319
Ruth M. Greenblatt, Monica Gandhi. Special issues regarding women with HIV infection. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:521-536.
320
Salim S. Abdool Karim. HIV prevention. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:113-121.
321
Carlos Del Rio. Prevention of Human Immunodeficiency Virus Infection. In: Goldman's Cecil Medicine. Elsevier, 2012:2182-2185.
322
Gabriel R Galindo, Ja’Nina J Walker, Patrick Hazelton, Tim Lane, Wayne T Steward, Stephen F Morin, Emily A Arnold. (2012) Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implementation Science 7:1, 116
323
Mary Jo Hoyt, Deborah S. Storm, Erika Aaron, Jean Anderson. (2012) Preconception and Contraceptive Care for Women Living with HIV. Infectious Diseases in Obstetrics and Gynecology 2012, 1-14
324
J. D. Shelton. (2011) ARVs as HIV Prevention: A Tough Road to Wide Impact. Science 334:6063, 1645-1646
325
J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases 53:suppl 3, S64-S78
326
C. B. Hurt, J. J. Eron, M. S. Cohen. (2011) Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. Clinical Infectious Diseases 53:12, 1265-1270
327
Ronald A. Brooks, Raphael J. Landovitz, Rachel L. Kaplan, Eli Lieber, Sung-Jae Lee, Thomas W. Barkley. (2011) Sexual Risk Behaviors and Acceptability of HIV Pre-exposure Prophylaxis Among HIV-Negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study. AIDS Patient Care and STDs111207094037003
328
K. B. Patterson, H. A. Prince, E. Kraft, A. J. Jenkins, N. J. Shaheen, J. F. Rooney, M. S. Cohen, A. D. M. Kashuba. (2011) Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. Science Translational Medicine 3:112, 112re4-112re4
329
Iryna B. Zablotska, Garrett Prestage, Martin Holt, Mary Poynten, John de Wit, Rebecca Guy, Limin Mao, John McAllister, Andrew E. Grulich. (2011) Australian Gay Men Who Have Taken Nonoccupational Postexposure Prophylaxis for HIV Are in Need of Effective HIV Prevention Methods. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:4, 424-428
330
B. E. Nichols, C. A. B. Boucher, D. A. M. C. van de Vijver. (2011) HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. Journal of Internal Medicine 270:6, 532-549
331
Salim S Abdool Karim, Quarraisha Abdool Karim. (2011) Antiretroviral prophylaxis: a defining moment in HIV control. The Lancet 378:9809, e23-e25
332
Ronald O. Valdiserri. (2011) Commentary: Thirty Years of AIDS in America: A Story of Infinite Hope. AIDS Education and Prevention 23:6, 479-494
333
Roger Detels, Dean L. Winslow. (2011) Treatment as Prevention. AIDS1
334
Thomas C. Quinn. (2011) The 30-Year War on AIDS: Have We Reached the Tipping Point?. Sexually Transmitted Diseases 38:12, 1089-1093
335
Ming Li, Dorothy L. Patton, Yvonne Cosgrove-Sweeney, Deena Ratner, Lisa C. Rohan, Alexander M. Cole, Patrick M. Tarwater, Phalguni Gupta, Bharat Ramratnam. (2011) Incorporation of the HIV-1 Microbicide Cyanovirin-N in a Food Product. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:4, 379-384
336
James A. McIntyre. (2011) Can Devices for Adult Male Circumcision Help Bridge the Implementation Gap for HIV Prevention Services?. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:5, 506-508
337
Girish N. Vyas, Cheryl A. Stoddart, M. Scott Killian, Todd V. Brennan, Tiffany Goldberg, Alyssa Ziman, Yvonne Bryson. (2011) Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies. Biologicals
338
Stefano Rusconi. (2011) Investigators Involvement in the Care of HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:4, e118-e119
339
Jie Yang, Lin Li, Suiyi Tan, Hong Jin, Jiayin Qiu, Qinchao Mao, Runming Li, Chenglai Xia, Zhi-Hong Jiang, Shibo Jiang, Shuwen Liu. (2011) A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: Potential applications for preventing HIV-1 infection. Fitoterapia
340
M. Scott Killian, Jay A. Levy. (2011) HIV/AIDS: 30 Years of progress and future challenges. European Journal of Immunology 41:12, 3401-3411
341
Douglas Krakower, Kenneth H. Mayer. (2011) Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications. Current HIV/AIDS Reports 8:4, 241-248
342
José Heuker, Gerard J.B. Sonder, Ineke Stolte, Ronald Geskus, Anneke Van Den Hoek. (2011) High HIV incidence among MSM prescribed postexposure prophylaxis in Amsterdam, 2000–2009. AIDS1
343
Nirupama Deshmane Sista, Quarraisha Abdool Karim, Kathy Hinson, Deborah Donnell, Susan H Eshleman, Sten H Vermund. (2011) Experience in international clinical research: the HIV Prevention Trials Network. Clinical Investigation 1:12, 1609-1618
344
Lindsay M Ferguson, Lisa Cencia Rohan. (2011) The importance of the vaginal delivery route for antiretrovirals in HIV prevention. Therapeutic Delivery 2:12, 1535-1550
345
Stefan Baral, Frangiscos Sifakis, Alena Peryskina, Vladimir Mogilnii, Nicole F. Masenior, Boris Sergeyev, Irina Deobald, Andrea L. Wirtz, Chris Beyrer. (2011) Risks for HIV Infection Among Gay, Bisexual, and Other Men Who Have Sex with Men in Moscow and St. Petersburg, Russia. AIDS Research and Human Retroviruses111116070158006
346
Nicolas Lorente, Lionel Fugon, Maria Patrizia Carrieri, Christian Andreo, Jean-Marie Le Gall, Emmanuel Cook, Jean-Pierre Aboulker, Catherine Capitant, Jean-Michel Molina, Bruno Spire. (2011) Acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care1-10
347
José das Neves, Johan Michiels, Kevin K. Ariën, Guido Vanham, Mansoor Amiji, Maria Fernanda Bahia, Bruno Sarmento. (2011) Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. Pharmaceutical Research
348
Connie J. Sexton, Elizabeth C. Costenbader, Dang Thi Nhat Vinh, Pai Lien Chen, Tran Vu Hoang, Nguyen Thi Hoang Lan, Paul Feldblum, Andrea Kim, Le Truong Giang. (2011) Correlation of Prospective and Cross-Sectional Measures of HIV Type 1 Incidence in a Higher-Risk Cohort in Ho Chi Minh City, Vietnam. AIDS Research and Human Retroviruses111109070851001
349
Beryl A. Koblin, Gordon Mansergh, Victoria Frye, Hong Van. Tieu, Donald R. Hoover, Sebastian Bonner, Stephen A. Flores, Sharon M. Hudson, Grant N. Colfax. (2011) Condom-Use Decision Making in the Context of Hypothetical Pre-Exposure Prophylaxis Efficacy Among Substance-Using Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, 319-327
350
Samuel B. Keller, Davey M. Smith. (2011) The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS 25:18, 2308-2310
351
S. Daou, A. Calmy. (2011) Le traitement prophylactique de l’infection par le virus de l’immunodéficience humaine (VIH). La Revue de Médecine Interne 32:11, 658-662
352
Lauren L. Katzen, José A. Fernández-Romero, Avina Sarna, Kailapuri G. Murugavel, Daniel Gawarecki, Thomas M. Zydowsky, Barbara S. Mensch. (2011) Validation of a Dye Stain Assay for Vaginally Inserted Hydroxyethylcellulose-Filled Microbicide Applicators. Sexually Transmitted Diseases 38:11, 1050-1055
353
P. Volberding. (2011) The impact of HIV research on health outcome and healthcare policy. Annals of Oncology 22:Suppl 7, vii50-vii53
354
Felicity Daly. (2011) The introduction of new antiretroviral-based HIV prevention methods into health systems: key issues. Reproductive Health Matters 19:38, 208-212
355
A. J. Leigh Brown, S. J. Lycett, L. Weinert, G. J. Hughes, E. Fearnhill, D. T. Dunn, . (2011) Transmission Network Parameters Estimated From HIV Sequences for a Nationwide Epidemic. Journal of Infectious Diseases 204:9, 1463-1469
356
John Stover. (2011) 30 years after HIV identification: where to from here?. Expert Review of Anti-infective Therapy 9:11, 947-949
357
Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen E. Gómez, Beatriz Perdiguero, Jose L. Nájera, Victoria Jiménez, Juan García-Arriaza, Alberto C. Guardo, Iñaki Pérez, Vicens Díaz-Brito, Matilde Sánchez Conde, Nuria González, Amparo Alvarez, José Alcamí, José Luis Jiménez, Judit Pich, Joan Albert Arnaiz, María J. Maleno, Agathe León, María Angeles Muñoz-Fernández, Peter Liljeström, Jonathan Weber, Giuseppe Pantaleo, José M. Gatell, Montserrat Plana, Mariano Esteban. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29:46, 8309-8316
358
Graciela Andrei, Andrea Lisco, Christophe Vanpouille, Andrea Introini, Emanuela Balestra, Joost van den Oord, Tomas Cihlar, Carlo-Federico Perno, Robert Snoeck, Leonid Margolis, Jan Balzarini. (2011) Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication. Cell Host & Microbe 10:4, 379-389
359
Rúbia Marília de Medeiros, Dennis Maletich Junqueira, Maria Cristina Cotta Matte, Nêmora Tregnago Barcellos, José Artur Bogo Chies, Sabrina Esteves Matos Almeida. (2011) Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: Analysis of primary resistance mutations. Journal of Medical Virology 83:10, 1682-1688
360
Pietro L. Vernazza, Irma Graf, Ulrike Sonnenberg-Schwan, Maria Geit, Anja Meurer. (2011) Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS 25:16, 2005-2008
361
Harkaitz Azkune, Maialen Ibarguren, Xabier Camino, José Antonio Iribarren. (2011) Prevención de la transmisión del VIH (vertical, ocupacional y no ocupacional). Enfermedades Infecciosas y Microbiología Clínica 29:8, 615-625
362
José Vicente Fernández-Montero, Vicente Soriano. (2011) Profilaxis preexposición en la prevención de la infección por virus de la inmunodeficiencia humana. Medicina Clínica 137:10, 446-448
363
Robert T Koppenhaver, Stephen W Sorensen, Paul G Farnham, Stephanie L Sansom. (2011) The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex With Men in the United States: An Epidemic Model. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, e51-e52
364
Rewa Kohli, Sharon Tsui, Sanjay Mehendale, Elizabeth Tolley. (2011) Indian married men's interest in microbicide use. AIDS Care 23:10, 1344-1349
365
Lane R. Bushman, Jennifer J. Kiser, Joseph E. Rower, Brandon Klein, Jia-Hua Zheng, Michelle L. Ray, Peter L. Anderson. (2011) Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC–MS/MS detection. Journal of Pharmaceutical and Biomedical Analysis 56:2, 390-401
366
S. A. Springer, A. C. Spaulding, J. P. Meyer, F. L. Altice. (2011) Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 53:5, 469-479
367
Vitaly A. Kushnir, William Lewis. (2011) Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertility and Sterility 96:3, 546-553
368
Nicole Stolte-Leeb, Roberta Loddo, Sophia Antimisiaris, Tina Schultheiss, Ulrike Sauermann, Monika Franz, Spyridon Mourtas, Christophe Parsy, Richard Storer, Paolo La Colla, Christiane Stahl-Hennig. (2011) Topical Nonnucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of Macaques. AIDS Research and Human Retroviruses 27:9, 933-943
369
Leolin Katsidzira, James G. Hakim. (2011) HIV prevention in southern Africa: why we must reassess our strategies?. Tropical Medicine & International Health 16:9, 1120-1130
370
Hammer , Scott M. , . (2011) Antiretroviral Treatment as Prevention. New England Journal of Medicine 365:6, 561-562
Free Full Text371
Andrew Anglemyer, George W Rutherford, Rachel C Baggaley, Matthias Egger, Nandi Siegfried, George W Rutherford. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
372
Kyeen M. Andersson, John Stover. (2011) The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine 29:36, 6092-6099
373
AR Giuliano, MF Schim van der Loeff, AG Nyitray. (2011) Circumcised HIV-infected men and HPV transmission. The Lancet Infectious Diseases 11:8, 581-582
374
Nico J.D. Nagelkerke, Jan A.C. Hontelez, Sake J. de Vlas. (2011) The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study. Vaccine 29:36, 6079-6085
375
Richard T. Gray, Mohammad H. Ghaus, Alexander Hoare, David P. Wilson. (2011) Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Vaccine 29:36, 6125-6129
376
Kelly A Curtis, M Susan Kennedy, Amara Luckay, Mian-er Cong, Ae S Youngpairoj, Qi Zheng, James Smith, Debra Hanson, Walid Heneine, S Michele Owen, J Gerardo García-Lerma. (2011) Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes 57:5, 355-362
377
Marc P. Girard, Saladin Osmanov, Olga M. Assossou, Marie-Paule Kieny. (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 29:37, 6191-6218
378
Kevin M De Cock, Wafaa M El-Sadr, Tedros A Ghebreyesus. (2011) Game Changers: Why Did the Scale-Up of HIV Treatment Work Despite Weak Health Systems?. JAIDS Journal of Acquired Immune Deficiency Syndromes 57, S61-S63
379
Sten H Vermund. (2011) Modeling interventions to assess HIV epidemic impact in Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes1
380
Paula M. Frew, Matthew Archibald, Brooke Hixson, Carlos del Rio. (2011) Socioecological influences on community involvement in HIV vaccine research. Vaccine 29:36, 6136-6143
381
Gita Ramjee. (2011) Antiretroviral-based microbicides and oral pre-exposure prophylaxis for HIV prevention. Future Virology 6:8, 997-1014
382
Gerard van den Aardweg. (2011) On the Psychogenesis of Homosexuality. The Linacre Quarterly 78:3, 330-354
383
Gerard van den Aardweg. (2011) Abuse by Priests, Homosexuality, <i>Humanae vitae</i>, and a Crisis of Masculinity in the Church. The Linacre Quarterly 78:3, 274-293
384
Reinhard H. Dennin, Michael Lafrenz, Arndt Sinn, Lan-juan Li. (2011) Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights. Journal of Zhejiang University SCIENCE B 12:7, 591-610
385
Kenneth H Mayer. (2011) Antiretrovirals for HIV prevention: translating promise into praxis. The Lancet 378:9787, 206-208
386
Sheldon R Morris, Susan J Little. (2011) MSM: resurgent epidemics. Current Opinion in HIV and AIDS 6:4, 326-332
387
Salim S Abdool Karim, Angela DM Kashuba, Lise Werner, Quarraisha Abdool Karim. (2011) Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. The Lancet 378:9787, 279-281
388
Louise Kuhn, Ida Susser, Zena Stein. (2011) Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified?. The Lancet 378:9787, 285-287
389
Nancy S Padian, Sandra I McCoy, Salim S Abdool Karim, Nina Hasen, Julia Kim, Michael Bartos, Elly Katabira, Stefano M Bertozzi, Bernhard Schwartländer, Myron S Cohen. (2011) HIV prevention transformed: the new prevention research agenda. The Lancet 378:9787, 269-278
390
Erik De Clercq. (2011) The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochemical Pharmacology 82:2, 99-109
391
John Imrie, Frank Tanser. (2011) Targeting strategies and behavior change to combat the HIV epidemic in southern Africa. Future Virology 6:7, 793-800
392
Laurent Bélec, Mohammad-Ali Jenabian, Charlotte Charpentier, Hela Saïdi. (2011) Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiology 6:7, 731-737
393
Merlin Robb. (2011) HIV vaccine development: a new beginning. Expert Review of Vaccines 10:7, 925-927
394
R. J. Shattock, M. Warren, S. McCormack, C. A. Hankins. (2011) Turning the Tide Against HIV. Science 333:6038, 42-43
395
Salim S. Abdool Karim. (2011) Stigma impedes AIDS prevention. Nature 474:7349, 29-31
396
(2011) A big disease with a little name. Nature 474:7349, 5-5
397
Kumi Smith, Kimberly A Powers, Angela DM Kashuba, Myron S Cohen. (2011) HIV-1 treatment as prevention: the good, the bad, and the challenges. Current Opinion in HIV and AIDS1
398
Theodoros Kelesidis, Raphael J. Landovitz. (2011) Preexposure Prophylaxis for HIV Prevention. Current HIV/AIDS Reports 8:2, 94-103
399
Meredith R. Clark, Patrick F. Kiser, Andrew Loxley, Christopher McConville, R. Karl Malcolm, David R. Friend. (2011) Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. Drug Delivery and Translational Research 1:3, 238-246
400
Natasha A. Verma, Anna C. Lee, Betsy C. Herold, Marla J. Keller. (2011) Topical Prophylaxis for HIV Prevention in Women: Becoming a Reality. Current HIV/AIDS Reports 8:2, 104-113
401
Arleen A. Leibowitz, Karen Byrnes Parker, Mary Jane Rotheram-Borus. (2011) A US Policy Perspective on Oral Preexposure Prophylaxis for HIV. American Journal of Public Health 101:6, 982-985
402
Y. Omar Whiteside, Tammy Harris, Christopher Scanlon, Stephen Clarkson, Wayne Duffus. (2011) Self-Perceived Risk of HIV Infection and Attitudes About Preexposure Prophylaxis Among Sexually Transmitted Disease Clinic Attendees in South Carolina. AIDS Patient Care and STDs 25:6, 365-370
403
J. B. F. de Wit, P. Aggleton, T. Myers, M. Crewe. (2011) The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. Health Education Research 26:3, 381-392
404
Margaret A. Lampe, Dawn K. Smith, Gillian J.E. Anderson, Ashley E. Edwards, Steven R. Nesheim. (2011) Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. American Journal of Obstetrics and Gynecology 204:6, 488.e1-488.e8
405
Cohen , Myron S. , Shaw , George M. , McMichael , Andrew J. , Haynes , Barton F. , . (2011) Acute HIV-1 Infection. New England Journal of Medicine 364:20, 1943-1954
Full Text406
Andrew Anglemyer, George W Rutherford, Matthias Egger, Nandi Siegfried, George W Rutherford. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
407
HimaBindu Chunduri, Clyde Crumpacker, Prem L. Sharma. (2011) Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. Virology 414:1, 34-41
408
Jessica E. Price, Willard Cates. (2011) Sex Worker Studies: The Science, Semantics, and Politics of Targeting Our HIV Prevention Response. Sexually Transmitted Diseases 38:5, 395-397
409
Mark A Wainberg, Hugh J Field. (2011) Proof of principle: antiretroviral drugs can prevent sexual transmission of HIV-1. Future Virology 6:5, 549-551
410
Barry R O’Keefe. (2011) Anti-HIV microbicide development: targeting the virus is the key. Future Virology 6:5, 553-556
411
(2011) Preexposure Chemoprophylaxis for HIV Prevention. New England Journal of Medicine 364:14, 1372-1375
Free Full Text412
P. Anton, B. C. Herold. (2011) HIV Transmission: Time for Translational Studies to Bridge the Gap. Science Translational Medicine 3:77, 77ps11-77ps11
413
Mian-er Cong, Ae S. Youngpairoj, Wutyi Aung, Sunita Sharma, James Mitchell, Charles Dobard, Walid Heneine, J. Gerardo Garcia-Lerma. (2011) Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques. Virology 412:2, 435-440
414
Elie Dolgin. (2011) Trial success spurs planning for rollout of HIV prevention pills. Nature Medicine 17:4, 392-392
415
Amanda Clarke, Reshmie Ramautarsing, Pirapon June Ohata, Denise Hsu, Nadia Kancheva Landolt, Stephen J Kerr, Anchalee Avihingsanon, Wirach Maek-a-nantawat, Thanyawee Puthanakit, Torsak Bunupuradah, Wasana Prasitsuebsai, Jintanat Ananworanich, Kiat Ruxrungtham. (2011) The 14th Bangkok International Symposium on HIV Medicine. Future Virology 6:4, 409-412
416
David Rey. (2011) Post-exposure prophylaxis for HIV infection. Expert Review of Anti-infective Therapy 9:4, 431-442
417
Rebecca F Baggaley, Kimberly A Powers, Marie-Claude Boily. (2011) What do mathematical models tell us about the emergence and spread of drug-resistant HIV?. Current Opinion in HIV and AIDS 6:2, 131-140
418
Kevin K. Ariën, Vicky Jespers, Guido Vanham. (2011) HIV sexual transmission and microbicides. Reviews in Medical Virology 21:2, 110-133
419
Brian S. Mustanski, Michael E. Newcomb, Steve N. Du Bois, Steve C. Garcia, Christian Grov. (2011) HIV in Young Men Who Have Sex with Men: A Review of Epidemiology, Risk and Protective Factors, and Interventions. Journal of Sex Research 48:2-3, 218-253
420
Gavin M. Myers, Kenneth H. Mayer. (2011) Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings. AIDS Patient Care and STDs 25:2, 63-71
421
S. H. Vermund, L. Van Damme. (2011) HIV Prevention in Women: Next Steps. Science 331:6015, 284-284
422
Mark A. Wainberg. (2011) AIDS: Drugs that prevent HIV infection. Nature 469:7330, 306-307
423
Barry D Adam. (2011) Epistemic fault lines in biomedical and social approaches to HIV prevention. Journal of the International AIDS Society 14:Suppl 2, S2
424
Richard G Wamai, Brian J Morris, Stefan A Bailis, David Sokal, Jeffrey D Klausner, Ross Appleton, Nelson Sewankambo, David A Cooper, John Bongaarts, Guy de Bruyn, Alex D Wodak, Joya Banerjee. (2011) Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. Journal of the International AIDS Society 14:1, 49
425
Rony Zachariah, Wim Van Damme, Vic Arendt, Jean Schmit, Anthony D Harries. (2011) The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research. Journal of the International AIDS Society 14:Suppl 1, S7
426
Erik De Clercq. (2011) Acyclic nucleoside phosphonates: An unfinished story. Collection of Czechoslovak Chemical Communications 76:7, 829-842
427
Robert Kalyesubula, Mark A. Perazella. (2011) Nephrotoxicity of HAART. AIDS Research and Treatment 2011, 1-11
428
Kathleen M MacQueen. (2011) Framing the social in biomedical HIV prevention trials: a 20-year retrospective. Journal of the International AIDS Society 14:Suppl 2, S3
429
Ram Yogev, Ellen Gould Chadwick. Acquired Immunodeficiency Syndrome (Human Immunodeficiency Virus). In: Nelson Textbook of Pediatrics. Elsevier, 2011:1157-1177.e1.
430
Brian Williams, Robin Wood, Victor Dukay, Wim Delva, David Ginsburg, John Hargrove, Martinus Stander, Robert Sheneberger, Julio Montaner, Alex Welte. (2011) Treatment as prevention: preparing the way. Journal of the International AIDS Society 14:Suppl 1, S6
431
Michael , Nelson L. , . (2010) Oral Preexposure Prophylaxis for HIV — Another Arrow in the Quiver?. New England Journal of Medicine 363:27, 2663-2665
Free Full Text
- Comments (8)
-
8 Reader's Comments
MR CHARLES KWOBAH, MD | Student | Disclosure: NoneNAIROBI KenyaNovember 26, 2010SITUATION IN SUBSAHARAN AFRICA
The results of this study, if implemented in sub saharan africa could lead to a difficult situation since emtricitabine and tenofovir are considered 2nd line treatment and using these drugs for PRexProphylaxis could lead to widespread resistance, especially when poor adherence issues are factored in.
Jim Pickett | Other | Disclosure: NoneNovember 24, 2010Need for a rectal gel option
So, the study team found that about half of the men in the active arm of the trial were in fact not taking their pills regularly, if at all. It is not clear why this happened, but it certainly suggests that alternate means of using ARVs to prevent HIV infection may be more acceptable for these men.
The primary means of transmission among gay men and other MSM is through unprotected anal intercourse. If we develop an ARV as a gel or lubricant applied rectally – a rectal microbicide – it could be more acceptable for some individuals who don’t like taking pills. Many gay men and other MSM already use lubricants for anal intercourse, so they wouldn’t have to modify their behavior to achieve higher levels of protection with a rectal microbicide formulated as a lubricant. Adopting a new behavior—such as taking a pill every day—can be a considerable challenge for some. Please visit the homepage of IRMA - International Rectal Microbicide Advocates http://www.rectalmicrobicides.org for more info on the research and development of this strategy - including advocacy activities underway.EUGENE SEMON | Other | Disclosure: NoneRIDGEFIELD PARK NJNovember 24, 2010Risk Equation
With all due respect to the hard work this study represents: its results appear to offer nothing new for the practicing clinician - which I'm not. (But I can question.) Are old problems for clinicians dealing with NIH recommendations re HIV still unsolved, e.g. the "hit hard and early" debate?
Shouldn't differential diagnosis at least identify potential "elite controllers" when considering "pre-exposure prophylaxis"? Do the calculated risks of acquiring a LETHAL infection, say a number like 5% per year per individual MSM, consider the number of "elite controllers" expected from such a set of cohorts? After all, "long term non-progressors", as reported in this journal and many others, have ZERO RISK of an active, presumably immuno-destructive and lethal infection.James Sullivan | Physician - Infectious Diseases | Disclosure: NoneNovember 23, 2010Wish less medicine could achieve same result
The cost of this intervention, and the possibility of doing harm to a healthy person, will limit the use of this intervention. The incidence of infections in the treated (and fairly adherent) group probably precludes trying a less expensive regimen, like "every Thursday, and then a dose after/at every sexual encounter," which would have cut the average use of drug in those treated by 50 to 80% (and therefore maybe cut the risks down, in addition to the expense). Someone will need to do a cost-benefit analysis showing if there is a savings to be had by delaying infection in persons with a 5% per year risk of infection. An algorithm of questions that identified which MSM might be valid candidates for the intervention is needed. In real life, the follow up won't be this intense, more likely q 3 or 4 months at best...which will increase the chance of engendering resistance in those with "breakthrough" infection, and which might result in less curbing of risky behavior than was seen during the study. I understand the fears that behavior will worsen because this option "permits" it, but this is the only thing that has worked convincingly so far in MSM. I do think true adherence would be better in an open label arm, with participant expectation of a benefit if they adhered. Perhaps a result better than 75% might actually be achievable under those conditions.
ilaboo lener | Other | Disclosure: NoneNovember 23, 2010A fantastic begining of the end of the begining
This title says it all for me.
Nick Williams | Other | Disclosure: NoneNovember 23, 2010Are you sure this worked? Doesn’t sound like it...
But there is a reduction in condom use in the research cohorts! When asked if they used pills faithfully study, participants said yes when the bio medical readings show the answer was actually no. Strikingly this lapse did not warrant a disqualification or a corruption of the study data? Similarly when asked if they used condoms, study participants said yes but they still got HIV. This is already a clinical research ethics issue which resulted in HIV infections because of bad study design wherein ethical questions were asked and ethical responses were given from respondents who had a preconceived knowledge of what it means, ethically, to tell an HIV researcher that you were using condoms less because you finally have access to PrEP. Additionally the threat of losing PrEP access, real or perceived is an ethical determinant and a possible driver of responses from enrollments. I would like to see incidence rates by study location for enrolled MSM population groups situated as a baseline to compare against sero-converts in the study. We can see if being in the study made you more likely to contract HIV than being in the MSM population by locality over time, as opposed to a cohort-based analysis that can't rule out study enrollment effects. The public health and ethical problems created by offering highly impacted populations a magic bullet for their ills is troubling and seductive, with obvious supplicant consequences. PrEP, on its best day is a complicated biomedical tool that should not stand in for a solution. This is what HIV prevention has come to: a Pharma advertisement for people who are not even infected yet and may be more likely to become so if you prescribe this to socially complicated, highly impacted patients and research subjects who have been waiting 30 years for a reprieve from a death sentence and celibacy.
DAVID COMPTON, MD | Physician - GENERAL PRACTICE | Disclosure: NoneWINGATE NCNovember 23, 2010Additional Protection
I understand the issue of additional protection, or any protection, in populations with a high incidence of HIV, but I worry that this will create a feeling of "I can't get it now" among those who take this chemoprophylaxis. Any subsequent reduction in the use of condoms by these individuals would be tragic.
- Letters
Can this study be generalized to all MSM?
This potentially life-or-death study retained about 68% of its subjects after 48 weeks, about 21% after 108 weeks, and about 5% after 132 weeks (Fig. 2). With such a high drop-out rate, it seems unlikely that the study-compliant are a representative sub-sample of the initial sample. With so many subjects 'missing-in-action,' the odds that this study has generated an approach that will work with most MSM are minimal.